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ABSTRACT 
Background: Recently, the growing epidemic of obesity is mirrored in the increasing incidence 
rate of T1D in children. However, the role of overweight in the progress of T1D is still unknown. 
Objective: To assess the relationship between the overweight status at onset and the insulin 
reserve in the first two years since diagnosis in children with T1D. 
Methods: One hundred sixty-eight children newly diagnosed with T1D, aged from 1.5 to 18.9 
years, with 2-years of follow-up, ≥4 autoantibodies measured at baseline, and onset C-peptide 
plus 3 or more follow-up measures were included in this study from the Children’s Hospital of 
Pittsburgh Registry (2004-2006). Baseline demographic and clinical characteristics were 
compared between overweight and non-overweight subjects. The change and the rate of change 
of C-peptide were evaluated. The contribution of being overweight to C-peptide levels and 
change in C-peptide from onset over time were estimated using linear mixed models adjusting 
for other covariates.  
Results: Among the 168 subjects with mean age at 9.7 years and mean onset C-peptide of 
0.76ng/mL, 22% (36) were overweight at onset with BMI ≥ 85th percentile. Onset C-peptide 
level of overweight subjects was higher than that of non-overweight (median: 0.88ng/mL vs. 
0.50ng/mL, P<0.0001). The highest C-peptide levels (median: 1.86ng/mL vs. 1.47ng/mL, 
P=0.30) were observed a 3 months, followed by a continuous decline reaching the lowest level at 
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24 months (median: 0.29ng/mL vs. 0.18ng/mL, P=0.13). Linear mixed models suggest that the 
overall mean rate of change of the overweight subjects was 0.7865ng/mL/months (95% C.I.: 
(0.2277, 1.3452), P=0.0062) compared to the non-overweight subjects adjusting for other 
baseline covariates. The differences of mean C-peptide levels between these two groups 
decreased as time passed and reached similar levels at the end of the second year.  
Conclusion: Compared to the non-overweight T1D children, overweight children had higher C-
peptide levels at 3, 6, 12, and 18 months after diagnosis; however, at 24 months, this difference 
was not statistically significant. 
Public health significance: Children with T1D who are overweight can benefit from the 
potential related target interventions to help them maintain or extend the duration of high C-
peptide level after receiving treatment.  
v
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1.0  INTRODUCTION 
1.1 TYPE 1 DIABETES 
1.1.1 Epidemiology 
Type 1 diabetes (T1D), once known as juvenile diabetes or insulin-dependent diabetes, is defined 
as an autoimmune disease characterized by dysfunction of the pancreatic β cells [1], which 
results in deficiency of insulin secretion and/or defects in insulin action [2]. T1D is a worldwide 
public health burden for children and adolescents. Undoubtedly, T1D is one of the most common 
chronic diseases in America among people under the age of 20, and its long-term complications 
usually threaten the patients’ quality of life. According to the findings from SEARCH, during 
2008-2009, in the United States, over 18,000 people aged under 20 years were newly diagnosed 
with T1D [3]. People with T1D have a much higher risk for heart attack, stroke, hypertension, 
kidney failure, and other chronic diseases [2, 3]. The extreme gravity of T1D continues to inspire 
numerous researchers to investigate its etiology.  
1.1.2 Risk factors 
The most common recognition concerning T1D is that it is a classic autoimmune disorder 
characterized by destruction of the pancreatic β cells [3], which is known as the insulin-
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producing cells. The residual β-cell function can be physiologically defined by the β-cell mass in 
vivo. A few studies show that at the time of the diagnosis of T1D the loss of β-cell mass can 
reach up to 90% [4, 5]. Yet, the exact mechanism that causes T1D is still unknown. The 
destruction is naturally initiated or mediated by islet-specific autoantibodies, including islet cell 
autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GAD), insulinoma associated 
2 autoantibodies (IA2), insulin autoantibodies (IAA), and recently described zinc transporter 
autoantibodies (ZnT8A) [1]. Several researchers have shown that about 90% to 95% of the new 
onsets of T1D present with at least one positive autoantibody, which is believed to be a potential 
predictor of the later development of T1D [6-9]. Additionally, T1D is primarily seen in 
genetically susceptible people, such as those with specific HLA alleles [10], who may be 
exposed to some unknown environmental agent that may trigger the disease, such as vitamin D 
deficiency, viral infections, and stress [11]. Other risk factors, including age, gender, and 
race/ethnicity, are also considered to be associated with the presence of T1D in children and 
adolescents [1].  
1.1.3 Overweight and type 1 diabetes 
Over the recent decades, the growing epidemic of obesity [12] is mirrored in the worldwide 
increasing the incidence rate of T1D in youths [13-18]. An observational study from Finland 
gave both the evidence of excessive weight gain to the high risk of T1D in children [15], and the 
link between insulin resistance, autoimmune, and excessive weight gains, which is known as the 
“accelerator hypothesis” [19]. Nevertheless, the underlying relationship between overweight and 
residual β-cell function is still unproved.  
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1.2 C-PEPTIDE AS A SURROGATE MEASURE OF RESIDUAL BETA-CELL 
FUNCTION IN TYPE 1 DIABETES 
The loss of β-cell function is displayed as the inadequate secretion of insulin that cannot 
maintain the normal glycemia level in pathophysiology. Yet, clinically, the direct measure of 
endogenous insulin, a marker of the residual function of the pancreas β cells, is limited [20]. On 
the other hand, a study shows that the measurement of C-peptide, which is co-secreted with 
endogenous insulin in a one-to-one molar ratio, can provide a valid and reliable measure of the 
residual β-cell function [20], and such a measurement has been widely used as the primary 
appropriate outcome in both clinical and observational studies of T1D [20-25].  
At diagnosis of T1D, patients always have a lower value of C-peptide, reflecting a low 
preservation of the pancreas β-cell function, and such value of C-peptide is thought to be related 
to some physiological indices, including age at diagnosis, gender, islet-specific autoantibodies at 
baseline, base control of metabolism, and genotype [20, 26-29]. However, the relationship 
between overweight status at onset and C-peptide level over time, and, if any, the effect of 
overweight on the preservation of β-cell function, are still unknown. The objective of this study 
is to assess the relationship between the overweight status at onset and insulin reserve during the 
first two years of diagnosis in children with T1D by using C-peptide as the primary endpoint. 
From the perspective of public health implication, this study will provide a new direction of 
potential interventions that can benefit the overweight children with T1D.  
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2.0  RESEARCH DESIGN AND METHODS 
2.1 SUBJECTS 
The study subjects diagnosed with clinical T1D were identified from the diabetes clinic at 
Children’s Hospital of Pittsburgh from January 1st, 2004 to December 31st, 2006, and accrued 
through the Children’s Hospital of Pittsburgh Registry. All participants are children aged < 19 
years. Inclusion criteria for this study were as follows: 1) informed consent, 2) diagnosis of T1D 
requiring insulin, and insulin treatment prior to hospital discharge, 3) available research 
laboratory results for at least four β-cell autoantibodies at baseline, including IAA, IA2, GAD, 
ICA human, and ZnT8A, and 4) available C-peptide at onset and at least three follow-ups.  
2.2 DEMOGRAPHIC AND CLINICAL DATA 
Clinical data at onset and follow-up within 3 months were obtained from hospital and research 
records including diagnosis date, blood draw date, age at diagnosis, gender, race, height, and 
weight. BMI percentiles and BMI z-scores were calculated based on the Centers for Disease 
Control and Prevention 2000 growth data, and overweight was defined as BMI ≥ 85th percentile 
adjusting for age and gender. Insulin dose for treatment was recorded for each follow-up.  
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In the original records, among the subjects recruited in this study, some had more than 
one blood samples corresponding to each request return visit (Appendix A1). According to the 
protocol, the clinical record that has the closest days since diagnosis to the proposed follow-up 
window was retained regardless the records at the diagnosis (e.g., the clinical record with the 
closest days since diagnosis to 90 days was retain as the single record for 3 months, 180 days for 
6 months). Multiple clinical records at diagnosis for each subject were combined into a single 
complete one as the onset record.  
2.3 ASSAYS 
Blood samples obtained at onset and/or follow-up within 3 months were assayed for glucose, 
glycated hemoglobin (HbA1c), C-peptide levels, and autoantibodies. IAA was measured only in 
samples that obtained within 1 week of diagnosis; GAD, IA2, ICA human, and ZnT8A were 
measured from blood samples obtained within 120 days. All the assays to be used have been 
evaluated in International and National workshops [30]. Sensitivities and specificities have been 
consistently 80-100% for ICA, GAD, and IA2, and been 60% and 93% for IAA [24]. Baseline 
autoantibodies were defined as the earliest valid clinical record for corresponding autoantibodies 
within the first 120 days since diagnosis.  
C-peptide for onset, 3 months, and each 6 monthly follow-up for 2 years were measured 
by RIA kit (Linco Research, St. Charles, MO) with a lower detection limit of 0.1ng/mL, 4.7% 
inter-assay coefficient, and 4.6% intra-assay coefficient [24]. Levels of >5.0ng/mL were re-
measured after dilutions. Levels below the detection of the device were replaced with the 
midpoint from 0 to the lower detection level [29].  
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2.4 STATISTICAL ANALYSIS 
2.4.1 Descriptive statistics for covariates 
The follow-up pattern for this study group was summarized. Demographic and clinical 
characteristics of study subjects were described by overweight status at onset. Data were 
summarized using means and SDs or medians and IQRs for continuous variables (e.g., age, C-
peptide), and frequencies and proportions for categorical variables such as race, gender, and 
number of positive autoantibodies at baseline. Student t tests were conducted to compare means 
of continuous variables with normal distribution between overweight and non-overweight 
subjects at onset. Wilcoxon-Mann-Whitney tests were conducted if continuous variables were 
non-normally distributed. The proportions of categorical variables between overweight and non-
overweight subjects were compared using Fisher’s exact test. 
Insulin dose-adjusted HbA1c (IDAA1c) is defined as follows: HbA1c (%) +[4*insulin 
dose (units/kg/24h)], which is a credible value to define the partial remission (PR) in T1D 
(IDAA1c≤9) [21, 31]. 
Combinations of positive autoantibodies at baseline were counted by number of positive 
autoantibodies at baseline. Frequencies and proportions in each category were given.  
2.4.2 C-peptide 
Follow-up patterns for C-peptide were summarized by descriptive statistics and boxplots for 
onset and each follow-up visit. Changes in C-peptide from onset, from 3-month visit, and from 
each subsequent visit for corresponding follow-ups were evaluated. Rates of change of C-peptide 
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were calculated as follows: the window based rate of change = the change in C-peptide / the 
length between two follow-up periods in months, and the exact rate of change = the change in C-
peptide / the difference of in days since diagnosis between two follow-up periods in months. For 
example, the window based rate of change of 3-month visit from onset = the change of C-peptide 
at 3 months from onset / 3 months. Trajectories of means and medians of C-peptide, change of 
C-peptide, and rate of change of C-peptide were also evaluated. Student t tests were used to 
assess the change or the rate of change being different from zero if the values were normally 
distributed. Wilcoxon signed rank tests or sign tests were conducted for such purpose if values 
were not normally distributed.  
The same analytic procedures were performed for subgroup analysis, including 
comparisons between overweight and non-overweight subjects at onset, subgroups defined by 
their change in their overweight status from onset to 3-month visit, and among subjects with 
different number of positive autoantibodies at baseline. Additionally, Wilcoxon-Mann-Whitney 
tests were used to compare difference between two independent samples, and Kruskal-Wallis 
tests were used to compare difference between more than two independent samples, and Dwass, 
Steel, Critchlow-Fligner tests were performed for pairwise comparisons if multiple samples 
shown significantly difference. All are designed for nonparametric data.  
Associations between follow-up C-peptide measures and baseline covariates were 
assessed with Spearman and Pearson correlations when both variables were continuous.  
2.4.3 Linear mixed models 
In linear mixed models, both fixed effects and random effects are included in a single model. 
They are able to model data in which the observations are not independent (i.e., repeated 
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measurements on the same units or measurements on clusters of related units). Random 
coefficients models, one type of mixed models, is an appropriate approach to modeling repeated 
measures data when the main interest of the study centers on the rate of change of the study 
endpoint over time among different study groups. It allows this rate of change to vary randomly 
between study units by fitting units and units*time interaction as random in the model, and 
regression curves can be fitted individually for each unit. Simply, the estimation of overall group 
effects and such group effects at each time points can be obtained in a single model. Moreover, 
the problems introduced by the presence of missing data are negligible since they can be 
assumed as missing at random.  
In the current study, both univariate and multivariate linear mixed models (i.e., random 
coefficients models) were fitted for two endpoints: C-peptide levels from 3 months and forwards 
and change of C-peptide from onset for 3-month follow-up and forwards. Univariate linear 
mixed models were fitted for covariates including time (treated as continuous in days, continuous 
in months, and categorical in months), age at diagnosis (both continuous and categorical), 
gender, IDAA1c at 3 months, overweight status at onset, overweight status at 3 months, and 
number of positive autoantibodies at baseline. For multivariate linear mixed models, baseline 
model were first established using continuous variables, IDAA1c at 3 months, age at diagnosis, 
and time variable in days or in months, and categorical variables, gender (male as reference) and 
number of positive autoantibodies at baseline (0 or 1 as reference). The effects of overweight 
status at onset over time were evaluated based on the baseline model, and Pearson residuals were 
evaluated for each model. Comparisons between overweight and non-overweight subjects at each 
time were estimated. The models were shown as follows. The spaghetti plots were plotted for 
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both observed and fitted values for C-peptide and change of C-peptide from onset for each 
subject, and an overall spline was also presented.  
All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), 
and significance level was compared to 0.05.  
 
Figure 1. Linear mixed models for C-peptide at 3 months and forwards and change of C-peptide from onset 
of 3-month visit and forwards 
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3.0  RESULTS 
3.1 SUBJECTS 
Among the total 201 complete new onsets, 198 participants had records at onset (<14 days since 
diagnosis), 192 participants had at least three antibodies measured at baseline, 184 participants 
had at least four antibodies measured at baseline, 182 participants had onset C-peptide and at 
least three follow-ups of C-peptide, and 168 participants had at least four antibodies measured at 
baseline and at least three follow-ups of C-peptide and the onset C-peptide (179 participants had 
at least three antibodies measured at baseline and at least three follow-ups of C-peptide and the 
onset C-peptide). The final 168 subjects (83.58% out of 201) were the analyzed subjects in this 
study. Approximately half of them (49.40%) had complete 2-year follow-up records. The onset 
records (<14 days) were obtained for all 168 participants. The mean length of follow-up for 
study subjects was 694.09 days. The 1-year loss-follow-up rate for this study was approximately 
10.71%, and 17.26% for 2-year follow-up.  
Table 1. The days since diagnosis in each visit time frame 
Visits N Mean SD Median 25th Pctl 75th Pctl Min Max 
<14 days 168 0 1 0 0 0 0 5 
3 months 165 69 12 66 62 74 46 118 
6 months 148 168 25 161 152 178 124 267 
12 months 150 360 30 355 338 379 277 442 
18 months 144 548 34 545 522 571 453 628 
24 months 139 723 34 723 699 746 641 804 
* Numbers are in days.  
11 
Table 2. Twelve follow-up patterns for study subjects (N=168) 
<14 days 3 months 6 months 12 months 18 months 24 months N (%) 
X X X X X X 83 (49.40) 
X X X X X . 26 (15.48) 
X X X X . X 19 (11.31) 
X X X . X X 14 (8.33) 
X X X . X . 1 (0.60) 
X X X . . X 2 (1.19) 
X X . X X X 17 (10.12) 
X X . X X . 1 (0.60) 
X X . X . X 1 (0.60) 
X X . . X X 1 (0.60) 
X . X X X . 1 (0.60) 
X . X X . X 2 (1.19) 
* X indicates that there is a clinical record for that follow-up.  
 
 
Figure 2. Number of subjects in each visit time frame 
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3.2 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF STUDY 
SUBJECTS AT BASELINE 
The demographic and clinical characteristics at baseline of the 168 study subjects of 201 
complete new onsets that with no less than 4 autoantibodies measured at baseline and more than 
3 follow-ups of C-peptide besides diagnosis measure were shown in Table 3. The 11 participants 
that excluded from current analysis with 3 autoantibodies measured at baseline, which was 
included in previous study [32], were not significantly different from the 168 subjects in the 
demographic and clinical characteristics at baseline (See in Appendix A1).  
Among the 168 subjects with mean age of 9.7 years, 92 (54.8%) were male, and 159 
(94.6%) were white. The overall mean HbA1c level of the study subjects at onset was 11.86%, 
which was higher than the normal level for children under 19 (around 8%), and at 3 months after 
initiation of insulin treatment showed better controlled at 7.5%. The IDAA1c at 3-month visit 
was 9.27, which was on the boundary of partial remission of T1D. The mean BMI% for the study 
population is 51.4 at onset and increased to 73.5 at 3 months. The mean number of positive 
autoantibodies at baseline was 2.8. Only 16 (9.5%) participants had all negative autoantibodies at 
baseline, and 58 (34.5%) had 4 or 5 positive autoantibodies at baseline. The combinations of 
positive autoantibodies were shown in Appendix A1.  
Thirty-six (22%) of the total 168 subjects were overweight at onset with BMI ≥ 85th 
percentile. The mean BMI% of overweight subjects at onset was approximately 2.4 times higher 
than that of non-overweight subjects at onset (94.0 vs. 39.3). This ratio was shrunk to 1.4 at 3-
month visit (94.2 vs. 68.2). All the baseline characteristics were not statistically significant 
different between the overweight subjects and non-overweight subjects at onset, regardless of the 
BMI related measures.  
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Table 3. Baseline demographic and clinical characteristics of study subjects by overweight status at onset 
(N=168) 
Characteristics Overall  
(N=168) 
BMI ≥ 85th Pctl 
(N=36, 22%) 
BMI < 85th Pctl 
(N=127, 78%) 
P value 
Demographic     
Age at diagnosis, yrs 9.7 ± 3.7 9.77 ± 3.85 10.07 ± 2.42 0.64B 
Age group, yrs, n (%)    0.29 
       0-4 18 (10.71) 1 (2.78) 14 (11.02)  
       5-9 68 (40.48) 16 (44.44) 51 (40.16)  
       10-14 69 (41.07) 18 (50.00) 51 (40.16)  
       ≥ 15 13 (7.74) 1 (2.78) 11 (8.66)  
Gender, n (%)    0.71 
       Male 92 (54.76) 19 (52.78) 72 (56.69)  
       Female 76 (45.24) 17 (47.22) 55 (43.31)  
Race, n (%)    0.52 
       White 159 (94.64) 33 (91.67) 121 (95.28)  
       Black 8 (4.76) 3 (8.33) 5 (3.94)  
       Other 1 (0.60) 0 (0.00) 1 (0.79)  
BMI at onset, kg/m2 18.26 ± 4.42a 24.04 ± 4.86 16.62 ± 2.53 <0.0001B 
BMI at 3 months, kg/m2 19.78 ± 4.08b 24.60 ± 5.01i 18.47 ± 2.56j <0.0001B 
BMI % at onset 51.40 ± 32.61a 94.00 ± 4.75 39.33 ± 26.37 <0.0001B 
BMI % at 3 months 73.48 ± 20.03b 94.16 ± 6.74i 68.17 ± 18.43j <0.0001B 
BMI z-score at onset 0.03 ± 1.29a 1.73 ± 0.51 -0.45 ± 1.00 <0.0001B 
BMI z-score at 3 months 0.80 ± 0.76b 1.78 ± 0.53i 0.54 ± 0.56j <0.0001A 
Clinical     
HbA1c at onset 11.86 ± 2.37a 11.61 ± 2.15g 11.94 ± 2.44h 0.53B 
HbA1c at 3 months 7.30 ± 0.83d 7.12 ± 0.98i 7.35 ± 0.75h 0.22A 
IDAA1c at 3 months 9.27 ± 1.55c 9.04 ± 1.93k 9.33 ± 1.43l 0.09B 
Positive antibodies at 
baseline, n (%) 
   0.54 
       0 16 (9.52) 4 (11.11) 11 (8.66)  
       1 13 (7.74) 1 (2.78) 11 (8.66)  
       2 27 (16.07) 5 (13.89) 22 (17.32)  
       3 54 (32.14) 15 (41.67) 37 (29.13)  
       4 or 5 58 (34.53) 11 (30.56) 46 (36.22)  
Autoantibodies at baseline, 
n (%) 
    
       + IAA 31(56.36)e 6 (54.55)m 25 (56.82)n 1.00 
       + IA2 115 (68.45) 23 (63.89) 89 (70.08) 0.54 
       + GAD 89 (52.98) 21 (58.33) 67 (52.76) 0.56 
       + ICA human 135 (80.36) 28 (77.78) 103 (81.10) 0.64 
       + ZnT8A 100 (60.24)f 23 (63.89) 74 (59.20)j 0.70 
* Data are mean ± SD unless otherwise noted. P values for continuous covariates are obtained from Atwo-sample t-
tests for normal distribution, and BWilcoxon-Mann-Whitney tests for non-normal distribution. P values for 
categorical covariates are obtained from Fisher’s exact tests. IDAA1c, insulin dose-adjusted HbA1c.  
a Based on 163 subjects. b Based on 161 subjects. c Based on 146 subjects. d Based on 164 subjects. e Based on 55 
subjects. f Based on 166 subjects.  g Based on 35 subjects. h Based on 126 subjects. i Based on 33 subjects. j Based 
on 125 subjects. k Based on 30 subjects. l Based on 114 subjects. m Based on 11 subjects. n Based on 44 subjects. 
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3.3 C-PEPTIDE AT ONSET AND FOLLOW-UP VISITS 
3.3.1 C-peptide levels at onset and each follow-up 
The description of the C-peptide level at each follow-up was shown in Table 4. The mean level 
of C-peptide at onset in the study population was 0.76ng/mL (median: 0.57ng/mL). During the 2-
year follow-up since diagnosis of T1D (Figure 3), the C-peptide of study subjects reached the 
highest level at 3 months as 1.92±1.58ng/mL (median: 1.53ng/mL) and continuously decreased 
at following visits, and attained the lowest level at the end of the two-year follow-up at 
0.59±0.78ng/mL (median: 0.19ng/mL).  
Table 4. C-peptide of study subjects at each visit time frame 
Visits N Mean SD Median 25th Pctl 75th Pctl Min Max 
<14 days 168 0.76 0.46 0.57 0.50 0.87 0.25 3.85 
3 months 157 1.92 1.58 1.53 0.80 2.83 0.10 10.20 
6 months 139 1.68 1.43 1.34 0.63 2.23 0.10 7.73 
12 months 141 1.17 1.21 0.78 0.34 1.48 0.10 5.56 
18 months 133 0.98 1.24 0.47 0.10 1.25 0.10 6.11 
24 months 135 0.59 0.78 0.19 0.10 0.75 0.10 3.69 
* Values are in ng/mL. 
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Figure 3. C-peptide of study subjects at each visit time frame 
+ and ⋄ are the mean and median values of C-peptide of the study subjects at each visit time frame. ∘ are the extreme 
values greater than the Q3+1.5IQR of each visit.  
3.3.2 Change of C-peptide  
The mean changes of C-peptide from onset of 3 months to 18 months indicated that the C-
peptide level at 3 months to 18 months were greater than that at onset and the change rates 
decreased from 3 months to 18 months as 1.16ng/mL (median: 0.84ng/mL, P<0.0001), 
0.94ng/mL (median: 0.67ng/mL, P<0.0001), 0.40ng/mL (median: 0.10ng/mL, P=0.15), and 
0.24ng/mL (median: -0.11ng/mL, P=0.22), respectively; while at 24 months, the C-peptide level 
was less than onset with the mean change of -0.15ng/mL and median change of -0.40ng/mL 
(P<0.0001) (Table 5A). The increment of C-peptide from onset of 3 months was the largest one 
among all the 2-year follow-ups. However, such an increment lasted for a short time in current 
16 
study, since the C-peptide continuously decreased for the next follow-up periods (Table 5B), 
with mean change from 3-month visit of -0.21±1.33ng/mL (median: -0.29ng/mL, P<0.01), -
0.81±1.44ng/mL (median: -0.67ng/mL, P<0.0001), -0.89±1.44ng/mL (median: -0.82ng/mL, 
P<0.0001), and -1.37±1.40ng/mL (median: -1.07ng/mL, P<0.0001) for 6-month to 24-month 
visit separately.  
All the medians of change of each visit to the next follow-up were significantly different 
from 0 (all P<0.01) (Table 5C). Since diagnosis, C-peptide increased by 1.16ng/mL (median: 
0.84ng/mL) within 3 months, and then started to decrease for each interval between two 
subsequent visits. The decline from 6-month visit to 12-month visit was the fastest one with 
0.56ng/mL decrement (median: -0.42ng/mL). At 12-month and 24-month visit, the changes of C-
peptide from previous visit were not as greater as previous ones (Figure 4). 
Table 5. The change of C-peptide of each follow-up visit 
Visits N Mean ± SD Median [IQR] P value 
A. Change from onset 
3 months 157 1.16 ± 1.35 0.84 [0.16, 1.98] <0.0001c 
6 months 139 0.94 ± 1.32 0.67 [0.01, 1.52] <0.0001c 
12 months 141 0.40 ± 1.09 0.10 [-0.26, 0.73] 0.15c 
18 months 133 0.24 ± 1.04 -0.11 [-0.40, 0.60] 0.22c 
24 months 135 -0.15 ± 0.71 -0.40 [-0.45, 0.02] <0.0001c 
B. Change from 3 months 
6 months 129 -0.21 ± 1.33 -0.29 [-0.81, 0.38] <0.01b 
12 months 132 -0.81 ± 1.44 -0.67 [-1.50, -0.12] <0.0001b 
18 months 125 -0.89 ± 1.44 -0.82 [-1.90, -0.20] <0.0001a 
24 months 126 -1.37 ± 1.40 -1.07 [-2.31, -0.48] <0.0001c 
C. Change from each follow-up to subsequence 
Onset - 3 months 157 1.16 ± 1.35 0.84 [0.16, 1.98] <0.0001c 
3 months - 6 months 129 -0.21 ± 1.33 -0.29 [-0.81, 0.38] <0.01b 
6 months - 12 months 116 -0.56 ± 0.87 -0.42 [-1.11, -0.07] <0.0001b 
12 months - 18 months 111 -0.19 ± 0.74 -0.17 [-0.42, 0] <0.0001b 
18 months - 24 months 103 -0.33 ± 0.59 -0.14 [-0.47, 0] <0.0001c 
* Values are in ng/mL.  a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test.  
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Figure 4. The change of C-peptide 
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3.3.3 The rate of change of C-peptide  
The rates of change of C-peptide for each follow-up (calculated based on the length of follow-up 
window) were summarized in Table 6 and Figure 5. The mean increments of C-peptide from 
onset to 3-month, 6-month, 12-month, and 18-month visits were 0.39 (median: 0.28), 0.16 
(median: 0.11), 0.03 (median: 0.01), and 0.01 (median: -0.01) per unit per month, respectively, 
and the median rate of change of 3-month and 6-month visits were significantly different from 0 
(P<0.0001). While at 24-month window, by average, C-peptide decreased by 0.01ng/mL per 
month (median: -0.02, P<0.0001), which indicated the relapse of the function of beta cells in 
pancreas.  
The mean decrements of C-peptide from 3-month, to 6-month, 12-month, 18-month, and 
24-month follow-up visits were 0.07 (median: 0.10), 0.09 (median: 0.08), 0.06 (median: 0.05), 
and 0.07 (median: 0.05) per unit per month, respectively (all P<0.01 for mean or median values). 
Among all the follow-ups, the rate of change of C-peptide from 3-month visit to 12-month visit 
was the fastest one. After a year, the rate of decrement slowed down and stayed at a steady rate, 
but still significant.  
All the median rates of change of each visit to the next one were significantly different 
from 0 (all P<0.01). Since diagnosis, on average, C-peptide increased by 0.39ng/mL per month 
within 3 months (0.28ng/mL per month in median), and then started to decrease for each interval 
between two subsequent visits and the rate was maintained at around -0.05ng/mL per month.  
The summary for the rate of change divided by exact months interval was shown in 
Appendix A2, which present the same pattern here.  
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Table 6. The rate of change of C-peptide of each follow-up visit 
Visits N Mean ± SD Median [IQR] P value 
A. The rate of change from onset 
3 months 157 0.39 ± 0.45 0.28 [0.05, 0.66] <0.0001c 
6 months 139 0.16 ± 0.22 0.11 [0, 0.25] <0.0001c 
12 months 141 0.03 ± 0.09 0.01 [-0.02, 0.06] 0.15c 
18 months 133 0.01 ± 0.06 -0.01 [-0.02, 0.03] 0.22c 
24 months 135 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.0001c 
B. The rate of change from 3 months 
6 months 129 -0.07 ± 0.44 -0.10 [-0.27, 0.13] <0.01b 
12 months 132 -0.09 ± 0.16 -0.08 [-0.17, -0.01] <0.0001b 
18 months 125 -0.06 ± 0.10 -0.05 [-0.13, -0.01] <0.0001a 
24 months 126 -0.07 ± 0.07 -0.05 [-0.11, -0.02] <0.0001c 
C. The rate of change from each follow-up to subsequence 
Onset - 3 months 157 0.39 ± 0.45 0.28 [0.05, 0.66] <0.0001c 
3 months - 6 months 129 -0.07 ± 0.44 -0.10 [-0.27, 0.13] <0.01b 
6 months - 12 months 116 -0.09 ± 0.14 -0.07 [-0.18, -0.01] <0.0001b 
12 months - 18 months 111 -0.03 ± 0.12 -0.03 [-0.07, 0] <0.0001b 
18 months - 24 months 103 -0.06 ± 0.10 -0.02 [-0.08, 0] <0.0001c 
* Values are calculated by the change in a subject / the length of window between two follow-ups in months, in 
ng/mL/month.  a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test.  
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Figure 5. The rate of change of C-peptide 
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3.4 C-PEPTIDE AND OVERWEIGHT STATUS 
3.4.1 C-peptide and overweight status at onset 
C-peptide levels for each follow-up were summarized by overweight status at onset in Table 7. 
The patterns for overweight subjects and non-overweight subjects at onset were the same (Figure 
6). The onset C-peptide level of overweight subjects at onset was higher than that of non-
overweight subjects at onset (mean: 1.01ng/mL vs. 0.67ng/mL, median: 0.88ng/mL vs. 
0.50ng/mL, P<0.0001). At 3 months, both attained their highest C-peptide level (mean: 
2.53ng/mL vs. 1.74ng/mL, median: 1.86ng/mL vs. 1.47ng/mL, P=0.30). From then on, C-peptide 
level declined in both group and reached their lowest level (mean: 0.74ng/mL vs. 0.53ng/mL, 
median: 0.29ng/mL vs. 0.18ng/mL, P=0.13). However, overweight subjects had slight increase at 
18 months (mean: 1.63ng/mL, median: 1.16ng/mL), which was significantly different from the 
continuously decreased C-peptide level for non-overweight subjects (mean: 0.81ng/mL, median: 
0.45ng/mL) (P<0.01).  
The change and the rate of change (calculated based on the length of follow-up window) 
of C-peptide for each follow-up period by overweight status at onset were summarized in Table 
8 and 9. None show statistically significant difference between two groups except for the change 
from 18 months to 24 months, with the mean rates of -0.11ng/mL/month for overweight subjects 
at onset vs. -0.04ng/mL/months for non-overweight subjects at onset (median: -0.05 vs. -0.01 
with P=0.02). Graphically, the change and rate of change from onset among overweight subjects 
were slightly greater than that of non-overweight subjects. On the contrary, C-peptide of non-
overweight subjects decreased faster than overweight subjects from 3 months (Figure 6 and 7).  
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The summary for the rate of change divided by using exact months interval was shown in 
Appendix A3, which present the same pattern here. 
Table 7. C-peptide over follow-up visits among overweight and non-overweight subjects at onset (N=168) 
Visits Overweight at onset   Non-overweight at onset P value N Mean ± SD Median [IQR] N Mean ± SD Median [IQR] 
<14 days 36 1.01 ± 0.64 0.88 [0.60, 1.15] 127 0.67 ± 0.37 0.50 [0.50, 0.72] <0.0001 
3 months 33 2.53 ± 2.44 1.86 [0.55, 3.42] 119 1.74 ± 1.19 1.47 [0.80, 2.54] 0.30 
6 months 31 2.06 ± 1.65 1.58 [0.89, 3.64] 103 1.56 ± 1.32 1.29 [0.62, 2.15] 0.19 
12 months 29 1.52 ± 1.50 1.00 [0.43, 2.03] 108 1.07 ± 1.10 0.73 [0.32, 1.42] 0.16 
18 months 26 1.63 ± 1.69 1.16 [0.32, 2.46] 103 0.81 ± 1.04 0.45 [0.10, 0.95] <0.01 
24 months 31 0.74 ± 0.93 0.29 [0.11, 1.29] 100 0.53 ± 0.73 0.18 [0.10, 0.67] 0.13 
* Values are in ng/mL. P values are obtained from Wilcoxon-Mann-Whitney test for two independent samples. 
 
Figure 6. C-peptide over follow-up visits among overweight and non-overweight subjects at onset 
Indexes from left to right, top to bottom are as follows: A: C-peptide for each visit among overweight subjects at 
onset, B: C-peptide for each visit among overweight subjects at onset, C: trajectory of mean values for C-peptide 
among overweight and non-overweight subjects, D: trajectory of median values for C-peptide among overweight 
and non-overweight subjects. + and ⋄ are the mean and median values of C-peptide of the study subjects at each visit 
time frame. ∘ are the extreme values greater than the Q3+1.5IQR of each visit. C-peptide levels are positively 
skewed with mean > median in every follow-up visit. C-peptide at onset (P<0.01) and 18-month follow-up visit 
(P<0.0001) are significantly different between overweight and non-overweight subjects at onset. 
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Table 8. Change of C-peptide among overweight and non-overweight subjects at onset (N=168) 
Visits Overweight at onset   Non-overweight at onset P value* N Mean ± SD Median [IQR] P value N Mean ± SD Median [IQR] P value 
A. Change of C-peptide from onset 
3 months 33 1.54  ± 1.98 1.30 [-0.20, 2.14] 0.04c 119 1.06 ± 1.09 0.75 [0.22, 1.95] <0.0001b 0.69 
6 months 31 1.14 ± 1.55 0.69 [-0.03, 2.60] <0.001b 103 0.88 ± 1.24 0.53 [0.06, 1.48]  <0.0001c 0.61 
12 months 29 0.50 ± 1.19 0.11 [-0.16, 1.24] 0.26c 108 0.38 ± 1.06 0.11 [-0.26, 0.71] 0.25c 0.63 
18 months 26 0.61 ± 1.26 0.21 [-0.40, 1.17] 0.56c 103 0.15 ± 0.97 -0.15 [-0.40, 0.38] 0.11c 0.15 
24 months 31 -0.17 ± 0.84 -0.37 [-0.71, -0.02] <0.01c 100 -0.13 ± 0.67 -0.40 [-0.40, 0.01] <0.0001c 0.38 
B. Change of C-peptide from 3 months 
6 months 28 -0.34 ± 1.59 -0.53 [-1.17, 0.49] 0.26 a 96 -0.18 ± 1.28 -0.26 [-0.84, 0.38] 0.02 c 0.58 
12 months 27 -1.31 ± 1.90 -1.11 [-2.81, -0.12] <0.01a 101 -0.66 ± 1.29 -0.60 [-1.36, -0.09] <0.0001b 0.15 
18 months 25 -1.04 ± 2.00 -0.83 [-2.24, -0.10] 0.02 a 96 -0.84 ± 1.29 -0.82 [-1.71, -0.21] <0.0001b 0.69 
24 months 28 -1.62 ± 1.96 -1.59 [-2.70, -0.24] <0.001a 94 -1.28 ± 1.18 -1.04 [-2.27, -0.51] <0.0001a 0.51 
C. Change of C-peptide from each follow-up to subsequence 
3 months 33 1.54 ± 1.98 1.30 [-0.20, 2.14] 0.04 c 119 1.06 ± 1.09 0.75 [0.22, 1.95] <0.0001b 0.69 
6 months 28 -0.34 ± 1.59 -0.53 [-1.17, 0.49] 0.26 a 96 -0.18 ± 1.28 -0.26 [-0.84, 0.38] 0.02 c 0.58 
12 months 24 -0.74 ± 1.06 -0.50 [-1.49, -0.15] <0.01a 88 -0.50 ± 0.82 -0.38 [-1, -0.05] <0.0001b 0.35 
18 months 21 -0.12 ± 0.57 -0.02 [-0.38, 0.03] 0.35 a 87 -0.20 ± 0.79 -0.17 [-0.42, 0] <0.0001b 0.61 
24 months 22 -0.63 ± 0.79 -0.32 [-0.83, 0] 0.001c 78 -0.24 ± 0.48 -0.07 [-0.37, 0] <0.0001c 0.02 
* Values are in ng/mL. P values are obtained from Wilcoxon-Mann-Whitney test for two independent samples unless otherwise noted. a Based on t-test. b Based 
on Wilcoxon signed rank test. c Based on sign test. 
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Table 9. The rate of change of C-peptide among overweight and non-overweight subjects at onset (N=168) 
Visits Overweight at onset   Non-overweight at onset P value* N Mean ± SD Median [IQR] P value N Mean ± SD Median [IQR] P value 
A. Change of C-peptide from onset 
3 months 33 0.51 ± 0.66 0.43 [-0.07, 0.71] 0.04c 119 0.35 ± 0.36 0.25 [0.07, 0.65] <0.0001b 0.69 
6 months 31 0.19 ± 0.26 0.12 [-0.01, 0.43] <0.001b 103 0.15 ± 0.21 0.09 [0.01, 0.25] <0.0001c 0.61 
12 months 29 0.04 ± 0.10 0.01 [-0.01, 0.10] 0.26c 108 0.03 ± 0.09 0.01 [-0.02, 0.06] 0.25c 0.63 
18 months 26 0.03 ± 0.07 0.01 [-0.02, 0.07] 0.56c 103 0.01 ± 0.05 -0.01 [-0.02, 0.02] 0.11c 0.15 
24 months 31 -0.01 ± 0.03 -0.02 [-0.03, 0] <0.01c 100 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.0001c 0.38 
B. Change of C-peptide from 3 months 
6 months 28 -0.11 ± 0.53 -0.18 [-0.39, 0.16] 0.26 a 96 -0.06 ± 0.43 -0.09 [-0.28, 0.13] 0.02 c 0.58 
12 months 27 -0.15 ± 0.21 -0.12 [-0.31, -0.01] <0.01a 101 -0.07 ± 0.14 -0.07 [-0.15, -0.01] <0.0001b 0.15 
18 months 25 -0.07 ± 0.13 -0.06 [-0.15, -0.01] 0.02 a 96 -0.06 ± 0.09 -0.05 [-0.11, -0.01] <0.0001b 0.69 
24 months 28 -0.08 ± 0.09 -0.08 [-0.13, -0.01] <0.001a 94 -0.06 ± 0.06 -0.05 [-0.11, -0.02] <0.0001a 0.39a 
C. Change of C-peptide from each follow-up to subsequence 
3 months 33 0.51 ± 0.66 0.43 [-0.07, 0.71] 0.04 c 119 0.35 ± 0.36 0.25 [0.07, 0.65] <0.0001b 0.69 
6 months 28 -0.11 ± 0.53 -0.18 [-0.39, 0.16] 0.26 a 96 -0.06 ± 0.43 -0.09 [-0.28, 0.13] 0.02 c 0.58 
12 months 24 -0.12 ± 0.18 -0.08 [-0.25, -0.03] <0.01a 88 -0.08 ± 0.14 -0.06 [-0.17, -0.01] <0.0001b 0.35 
18 months 21 -0.02 ± 0.09 0 [-0.06, 0.01] 0.35 a 87 -0.03 ± 0.13 -0.03 [-0.07, 0] <0.0001b 0.61 
24 months 22 -0.11 ± 0.13 -0.05 [-0.14, 0] 0.001c 78 -0.04 ± 0.08 -0.01 [-0.06, 0] <0.0001c 0.02 
* Values are calculated by the change in subject / the length of window between two follow-ups in months, in ng/mL/month. P values are obtained from 
Wilcoxon-Mann-Whitney test for two independent samples unless otherwise noted. a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test.
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Figure 7. Change of C-peptide between two visits among overweight and non-overweight subjects at onset 
Left three are the trajectory of mean value of change of C-peptide from onset, 3 months, and previous visit, 
respectively. Right three are the trajectory of median value of change of C-peptide from onset, 3 months, and 
previous visit.  
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Figure 8. The rate of change of C-peptide between two visits among overweight and non-overweight subjects 
at onset 
 
Left three are the trajectory of mean value of the rate of change of C-peptide from onset, 3 months, and previous 
visit, respectively. Right three are the trajectory of median value of the rate of change of C-peptide from onset, 3 
months, and previous visit. 
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3.4.2 C-peptide and overweight status at onset and 3 months 
 
Table 10. C-peptide over follow-up visits among overweight status at onset and 3-month visit (N=168) 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
K-W 
K-W 
(exclude 
O - N) 
<14 days 
O - O 29 0.99 ± 0.64 0.82 [0.63, 1.03] 
<0.0001 <0.0001** O - N 4 1.31 ± 0.80 1.21 [0.70, 1.92] N - O 27 0.57 ± 0.12 0.50 [0.50, 0.61] 
N - N 98 0.70 ± 0.41 0.50 [0.50, 0.77] 
3 months 
O - O 29 2.30 ± 2.26 1.73 [0.45, 3.10] 
0.14 0.61 O - N 3 5.06 ± 3.66 3.81 [2.19, 9.18] N - O 27 1.54 ± 0.99 1.16 [0.63, 2.45] 
N - N 91 1.81 ± 1.24 1.49 [0.85, 2.59] 
6 months 
O - O 24 2.01 ± 1.72 1.29 [0.64, 3.66] 
0.39 0.36 O - N 4 2.27 ± 1.79 1.59 [1.27, 3.26] N - O 23 1.37 ± 1.34 0.81 [0.51, 2.09] 
N - N 79 1.61 ± 1.33 1.34 [0.67, 2.20] 
12 months 
O - O 23 1.48 ± 1.60 0.81 [0.34, 2.03] 
0.58 0.73 O - N 3 1.79 ± 1.53 1 [0.82, 3.56] N - O 22 1.21 ± 1.55 0.68 [0.25, 1.40] 
N - N 84 1.04 ± 0.97 0.76 [0.32, 1.50] 
18 months 
O - O 22 1.55 ± 1.71 1.16 [0.30, 2.19] 
0.02 0.07 O - N 3 2.65 ± 1.62 2.69 [1.01, 4.24] N - O 24 0.97 ± 1.50 0.34 [0.10, 1.01] 
N - N 77 0.74 ± 0.85 0.45 [0.10, 0.90] 
24 months 
O - O 24 0.72 ± 0.96 0.24 [0.10, 1.06] 
0.40 0.53 O - N 4 0.88 ± 0.97 0.55 [0.28, 1.49] N - O 22 0.54 ± 0.84 0.17 [0.10, 0.48] 
N - N 77 0.50 ± 0.67 0.16 [0.10, 0.66] 
Abbreviation: O – O: overweight – overweight, O – N: overweight – non-overweight, N – O: non-overweight – 
overweight, N – N: non-overweight – non-overweight. 
*Values are in ng/mL. P values are obtained from Kruskal-Wallis test and Dwass, Steel, Critchlow-Fligner test of 
pairwise comparison.  
** The differences among the three groups at onset exist between N – N vs. O – O (P<0.001), and N – O vs. O – O 
(P<0.0001). 
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Out of the 168 study subjects, 158 had available information of overweight status at both onset 
and 3-month follow-up. Out of the 127 non-overweight subjects at onset, 98 (62.0% of 158, 
77.2% of 127) were still non-overweight at 3-month follow-up, and 27 (17.1% of 158, 21.3% of 
127) became overweight at 3 months. Of the 36 overweight participants at onset, 29 (18.4% of 
158, 80.6 % of 36) were still overweight at 3-month follow-up, and only 4 participants (2.5% of 
158, 11.1% of 36) became non-overweight at 3-month follow-up (Table 10). Only at onset, the 
C-peptide levels were significantly different among the four groups (P<0.0001).  
C-peptide changes in the four groups of subjects followed the same pattern: C-peptide 
levels increased from onset to 3-month follow up visit and reached the high point at 3 months, 
and then gradually decreased after that until 24-month follow-up (Figure 9). The figure also 
shows that the overweight – non-overweight subjects had the highest values across the 2-year 
follow-ups; however, since there were only 4 participants in this group, this probably due to the 
extreme variability of C-peptide level. Regardless of the overweight – non-overweight group, 
overweight subjects at onset that remained overweight at 3-month visit tended to have higher C-
peptide levels than others. Additionally, subjects in overweight – overweight group also showed 
a same pattern as the overweight subjects at onset, of which C-peptide had a slightly jump-up at 
18-month visit. Graphically, the rate of decrease of C-peptide from 3-month visit to the 24-
month visit for subjects that were non-overweight at onset and changed to overweight at 3 
months presented lower levels than that among the subjects remaining non-overweight at 3-
month visit (Appendix A4).  
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Figure 9. Trajectory plot for mean and median of C-peptide for each combination of overweight status at 
onset and 3-month visit 
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3.5 C-PEPTIDE AND BASELINE AUTOANTIBODIES 
Table 11. C-peptide over follow-up visits among subjects with different number of positive antibodies at 
baseline (N=168) 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] P value 
<14 days 
0 16 0.90 ± 0.83 0.61 [0.50, 0.92] 
0.92 
1 13 0.73 ± 0.35 0.59 [0.50, 0.86] 
2 27 0.69 ± 0.28 0.50 [0.50, 0.88] 
3 54 0.76 ± 0.45 0.58 [0.50, 0.87] 
4 or 5 58 0.75 ± 0.44 0.56 [0.50, 0.87] 
3 months 
0 15 2.05 ± 2.44 1.16 [0.74, 2.38] 
0.43 
1 11 1.68 ± 1.45 1.47 [0.60, 2.01] 
2 26 2.25 ± 1.33 2.36 [0.94, 3.36] 
3 51 1.73 ± 1.40 1.48 [0.69, 2.48] 
4 or 5 54 1.94 ± 1.61 1.50 [0.77, 2.95] 
6 months 
0 11 1.88 ± 1.24 1.83 [0.65, 2.69] 
0.60 
1 11 2.03 ± 1.57 1.59 [0.99, 2.06] 
2 25 1.81 ± 1.44 1.60 [0.58, 2.37] 
3 46 1.65 ± 1.57 1.13 [0.67, 2.15] 
4 or 5 46 1.51 ± 1.30 1.11 [0.49, 2.22] 
12 months 
0 14 1.69 ± 1.50 1.42 [0.43, 2.35] 
0.20 
1 12 1.63 ± 1.58 0.99 [0.71, 2.10] 
2 26 1.17 ± 1.06 0.95 [0.34, 1.55] 
3 41 1.02 ± 1.16 0.68 [0.26, 1.18] 
4 or 5 48 1.04 ± 1.13 0.73 [0.29, 1.20] 
18 months 
0 12 1.66 ± 1.77 1.18 [0.48, 2.02] 
0.13 
1 9 1.43 ± 1.11 1.34 [0.56, 2.22] 
2 21 1 ± 1.42 0.58 [0.11, 1.01] 
3 44 0.86 ± 1.18 0.42 [0.10, 0.99] 
4 or 5 47 0.82 ± 1.03 0.32 [0.10, 1.13] 
24 months 
0 11 0.80 ± 0.85 0.53 [0.10, 1.15] 
0.51 
1 13 0.93 ± 0.99 0.48 [0.10, 1.66] 
2 22 0.63 ± 0.93 0.25 [0.10, 0.69] 
3 43 0.48 ± 0.67 0.19 [0.10, 0.66] 
4 or 5 46 0.52 ± 0.71 0.14 [0.10, 0.55] 
*Values are in ng/mL. P values are obtained from Kruskal-Wallis test. 
The C-peptide levels by autoantibodies status were examined in Table 11 grouped by the number 
of positive autoantibodies at baseline. All groups followed the same change pattern that C-
peptide reached the highest level at 3-month visit and then went down for following visits, and 
touched the lowest level at the end of the 2-year visit (Figure 10). In general, the less the number 
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of positive autoantibodies that the subjects had at baseline, the more C-peptide was produced as 
time passed and the slower the mean C-peptide level decreased from 3 months. (Appendix A5). 
Kruskal-Wallis Tests suggested that C-peptide levels were not significantly different among five 
autoantibody groups at onset and each follow up visit.  
 
Figure 10. Trajectory plot of mean and median of C-peptide at each follow-up by different number of positive 
autoantibodies at baseline 
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3.6 CORRELATIONS BETWEEN COVARIATES AND FOLLOW-UP C-PEPTIDE 
MEASURES 
The potential relationship between 2-year follow-up C-peptide levels and covariates, including 
age at diagnosis, gender, HbA1c at onset and 3 months, and IDAA1c at 3 months, were assessed 
in Table 12. Age at diagnosis was significantly positively correlated with each follow-up C-
peptide. HbA1c level is a useful determinant of how well the glycemia level has been controlled 
in the recent past in diabetes. The higher the glucose concentration in blood is, the higher the 
level of HbA1c is. The correlation coefficients of HbA1c at onset suggested that HbA1c was 
only significantly correlated with onset C-peptide (Pearson=-0.21, P<0.01 and Spearman=-0.19, 
P=0.01) while 3-month HbA1c was significantly negatively correlated with all C-peptide in 2-
year follow-up. Insulin dose-adjusted HbA1c (IDAA1c) is an indicator for partial remission in 
T1D [21], and can give more credible measure for the insulin reserve adjusting the effect of 
absorbed external insulin. In current study, 3-month IDAA1c shown a highly correlation with all 
C-peptide follow up levels [12]. Therefore, age at diagnosis, HbA1c at 3 months, and IDAA1c at 
3 months could be potentially predictors for the C-peptide levels at each follow-up.  
The correlations among age at diagnosis, HbA1c at 3 months, and IDAA1c at 3 months 
were also evaluated before fitting linear mixed models (Table 13). HbA1c at 3 months had 
statistical highly correlations with IDAA1c at 3-month follow-up (Pearson=0.72, P<0.0001, and 
Spearman=0.76, P<0.0001), whereas, there was no explicitly significant correlation between 3-
month IDAA1c and age at diagnosis (Pearson=0.03, P=0.75, and Spearman=-0.0008, P=0.99).  
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Table 12. Correlations between C-peptide over time and other covariates at baseline 
Covariate 
Pearson Correlation Coefficients (P value) 
Spearman Correlation Coefficients (P value) 
< 14 days 3 months 6 months 12 months 18 months 24 months 
Age at diagnosis, 
yrs 
0.24 
(<0.01) 
0.28 
(<0.01) 
0.42 
(<0.0001) 
0.44 
(<0.0001) 
0.46 
(<0.0001) 
0.47527 
(<0.0001) 
0.32 
(<0.0001) 
0.30 
(0.0001) 
0.45 
(<0.0001) 
0.42 
(<0.0001) 
0.53 
(<0.0001) 
0.49 
(<0.0001) 
HbA1c at onset -0.21 
(<0.01) 
-0.05 
(0.51) 
0.05 
(0.56) 
0.11 
(0.18) 
0.05 
(0.59) 
0.10 
(0.25) 
-0.19 
(0.01) 
-0.01 
(0.92) 
0.12 
(0.15) 
0.14 
(0.10) 
0.14 
(0.12) 
0.19 
(0.03) 
HbA1c at 3 
months 
-0.27 
(<0.001) 
-0.28 
(<0.001) 
-0.42 
(<0.0001) 
-0.37 
(<0.0001) 
-0.39 
(<0.0001) 
-0.32 
(<0.001) 
-0.26 
(<0.001) 
-0.27145 
(<0.001) 
-0.43 
(<0.0001) 
-0.42 
(<0.0001) 
-0.39 
(<0.0001) 
-0.32 
(<0.001) 
IDAA1c at 3 
months* 
-0.18 
(0.03) 
-0.28 
(<0.001) 
-0.37 
(<0.0001) 
-0.23 
(0.01) 
-0.18 
(0.05) 
-0.15 
(0.10) 
-0.21 
(0.01) 
-0.27 
(<0.01) 
-0.36 
(<0.0001) 
-0.40 
(<0.0001) 
-0.29 
(<0.01) 
-0.26 
(<0.01) 
* IDAA1c, insulin dose-adjusted HbA1c. 
^ P values are obtained from Kruskal-Wallis test.  
 
Table 13. Correlations among all the continuous covariates 
Pearson (P 
value) 
Spearman (P 
value) 
Age at 
diagnosis, 
yrs 
HbA1c at 
3 months 
IDAA1c at 
3 months 
Age at diagnosis, 
yrs 
 -0.21 
(<0.01) 
0.03 
(0.75) 
-0.21 
(<0.01) 
-0.0008 
(0.99) 
HbA1c at 3 
months 
  0.72 
(<0.0001) 
 0.76 
(<0.0001) 
IDAA1c at 3 
months 
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3.7 LINEAR MIXED MODELS FOR C-PEPTIDE AND CHANGE OF C-PEPTIDE 
FROM ONSET AT 3-MONTH VISIT AND FORWARD 
The estimates of multivariate analysis for C-peptide and change of C-peptide from onset at 3 
months and subsequent follow-ups using continuous visits as 3, 6, 12, 18, and 24 months were 
summarized in Table 14 and Table 15. The results for univariate models and multivariate 
analysis using time as days since diagnosis and categorical visits as 3, 6, 12, 18, and 24 months 
were presented in Appendix A6. All multivariate analysis for corresponding endpoint showed 
similar results.  
In the univariate analysis for endpoint as C-peptide at 3 months and forward, the clinical 
meaningful covariates, including age at diagnosis, IDAA1c at 3 months, and follow-ups were 
individually significant predictors (P<0.001), while gender and number of positive 
autoantibodies at onset (0-1 vs. 2+) were slightly non-significant (both P=0.08). Overweight at 
onset individually was a significant predictor (P=0.006). In the multivariate analysis, all the 
baseline covariates and overweight at onset were shown statistically significant effect on the 
prediction of C-peptide at 3 months and subsequent follow-ups. It suggested that, for a given 
time period, on average, older female overweight children at diagnosis with less than one number 
of positive autoantibodies at baseline and lower value of IDAA1c at 3 months would have a 
higher level of C-peptide than younger male non-overweight children at onset with more than 
one number of positive autoantibodies at baseline and higher value of IDAA1c at 3 months. The 
estimates in Table 15 showed that adjusting for other baseline covariates, the mean levels of C-
peptide at 3 months, 6 months, 12 months, and 18 months were significantly different between 
overweight and non-overweight subjects (with P=0.0045, 0.0033, 0.0030, and 0.0124 
respectively). However, at 24 months after insulin treatment, they were not statistically 
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significant (P=0.1055). At 3 months, the difference of mean C-peptide levels between 
overweight and non-overweight subjects was as high as 0.7281ng/mL (95%C.I.: (0.2300, 
1.2263)) and the differences became less in forward visits. The overall mean rate of change of C-
peptide for overweight subjects was 0.7865ng/mL/months (95% C.I.: (0.2277, 1.3452), 
P=0.0062) compared to non-overweight subjects sharing the same information for other baseline 
covariates.  
 
Table 14. Multivariate analysis for C-peptide and change of C-peptide from onset over 3 months and forward 
Covariates C-peptide at 3 months and forward 
Change of C-peptide from onset of 3 
months and forward 
Fixed effects (SE) P value Fixed effects (SE) P value 
IDAA1c at 3 months -0.1456 (0.04589) 0.0019 -0.1052 (0.04189) 0.0132 
Female 0.4374 (0.1461) 0.0033 0.2189 (0.1333) 0.1029 
Age at diagnosis 0.1428 (0.02017) <0.0001 0.1068 (0.01840) <0.0001 
2 or more Abs+ at baseline -0.4136 (0.1943) 0.0352 -0.2894 (0.1775) 0.1054 
Follow-up visits (in months) -0.05817 (0.006164) <0.0001 -0.05771 (0.006144) <0.0001 
Overweight at onset 0.7865 (0.2825) 0.0062 0.4505 (0.2528) 0.0771 
Overweight at onset * visits -0.01945 (0.01333) 0.1470 -0.01756 (0.01329) 0.1886 
*Model B: follow-up visits were coded as 3, 6, 12, 18, and 24 in months as continuous. 
 
Table 15. Comparison of estimated means of C-peptide and change of C-peptide from onset between 
overweight and non-overweight subjects at each follow-up 
 
Visits C-peptide  Change of C-peptide from onset  Difference of means (95% C.I.) P value Difference of means (95% C.I.) P value 
3 months 0.7281 (0.2300, 1.2263) 0.0045 0.3978 (-0.04307, 0.8386) 0.0766 
6 months 0.6698 (0.2264, 1.1132) 0.0033 0.3451 (-0.04352, 0.7337) 0.0813 
12 months 0.5531 (0.1910, 0.9152) 0.0030 0.2397 (-0.07913, 0.5586) 0.1394 
18 months 0.4364 (0.09613, 0.7767) 0.0124 0.1344 (-0.1853, 0.4541) 0.4071 
24 months 0.3197 (-0.06845, 0.7079) 0.1055 0.02902 (-0.3616, 0.4197) 0.8833 
Overall across time 0.7865 (0.2277, 1.3452) 0.0062 0.4505 (-0.04963, 0.9506) 0.0771 
* For model B: follow-up visits were coded as 3, 6, 12, 18, and 24 in months as continuous. Values are in ng/mL. P 
values were obtained from t-test for testing the estimates are different from 0 or not. 
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In the univariate analysis for endpoint as change in C-peptide from onset at 3 months and 
forward, overweight at onset individually was no longer a significant predictor (P=0.1612) 
(Appendix A6). In the multivariate analysis, the change level of C-peptide from onset was 
significantly related to IDAA1c at 3 months, age at diagnosis, and visits. Overweight was 
borderline non-significance (P=0.0771). It suggested that adjusting for other baseline covariates, 
the difference of mean change level of C-peptide from onset between overweight and non-
overweight subjects at 3 months (0.3978, 95%C.I.: (-0.04307, 0.8386)) was higher than any other 
visits. The overall mean increase of C-peptide from onset for overweight subjects could be 
0.4504ng/mL (95% C.I.: (-0.04963, 0.9506)) faster per month than in non-overweight subjects 
that share the same values for other covariates.  
The goodness-of-fit for each model was checked by spaghetti plots and Pearson residuals 
(Appendix A6). The plots in Figure 11 and 12 were comparing the observed values of C-peptide 
and change of C-peptide from onset at 3 months and forward follow-ups to the fitted values. 
While the model estimates were indeed very close to the observed values, there shows some 
underestimation using such a model.  
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Figure 11. Spaghetti plots for actual and fitted values of C-peptide at 3 months and forward follow-ups in 
Model B 
 
Left three are observed values for C-peptide. Right three are fitted values for C-peptide. Model B: follow-up visits 
were coded as 3, 6, 12, 18, and 24 in months as continuous. 
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Figure 12. Spaghetti plots for actual and fitted values of change of C-peptide from onset in Model B 
Left three are observed values for C-peptide. Right three are fitted values for C-peptide. Model B: follow-up visits 
were coded as 3, 6, 12, 18, and 24 in months as continuous. 
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4.0  DISCUSSION 
The underlying fundamental defect of T1D is the continuous loss of insulin secretion after 
diagnosis, which is an indicator of the impairment of the pancreatic β cells [1]. In the light of 
such a rationale, interventions that can slow or stop the destruction of pancreas β cells would 
delay or prevent the clinical onset of T1D. Several studies have found that the prevalence of 
overweight at onset among T1D children is increasing [14, 15, 24, 33]. However, the underlying 
relationship between overweight and residual β-cell function is still unproved. In this study, C-
peptide level, a surrogate endpoint for residual β-cell function, was used to investigate such a 
problem.  
The primary finding of this study is that after adjusting for other baseline covariates, 
compared to non-overweight T1D children, overweight children had higher C-peptide levels at 
period of 3, 6, 12, and 18 months after diagnosis; however, at 24 months this difference was not 
significant. The physiological mechanism for overweight patients to have higher C-peptide levels 
remains unknown. One possible conjecture is that overweight patients are usually diagnosed 
earlier than non-overweight patients [34]. Under such circumstance, the residual function of 
pancreas β cells would be better in overweight patients than in non-overweight patients.  
The mean BMI% for the study population was 51.4 at onset and increased to 73.5 at 3 
months. In the progress of T1D, subjects with preclinical T1D suffer dramatic weight loss before 
they are diagnosed, which is one of the most common symptoms of T1D (61%) [35]. After 
40 
receiving insulin treatment, their physical levels will return to normal, which is consistent with 
the presence of “honeymoon phase.” To better detect the relationship of the progress of the 
disease and the overweight status that the T1D children normally are, further analysis using 
overweight status at 3 months will be conducted.  
T1D is characterized by the autoimmune destruction of pancreas β cells. The production 
of islet autoantibodies reflects the magnitude of the autoimmunity. Among this study population, 
the mean number of positive autoantibodies at baseline was 2.8. Only 16 (9.5%) participants had 
all negative autoantibodies at baseline, and 58 (34.5%) had 4 or 5 positive autoantibodies at 
baseline. The statistical result of our study was consistent with earlier studies that high levels of 
islet antibodies are related to the rapid destruction of pancreas β cells and to the clinical onset of 
T1D [26, 36]. Additionally, through investigating the combination of all five positive 
autoantibodies in this study population, ICA human was mostly positive (80.4% of 168 subjects), 
which is in line with previous findings that the presence of ICA can be used as a surrogate 
marker to predict clinical T1D [37]. ZnT8A, a new marker discovered in recent years, also had a 
high present rate of 60.2% in this study. Various studies state that ZnT8A can improve the 
diagnosis and prediction of juvenile-onset T1D [38, 39]. Whether positive antibodies and 
overweight are associated or not need continued investigating.  
This study was a longitudinal study where patients were followed from onset to two years 
after the initiation of insulin treatment. Such an optimal study design enabled the inference on 
the relationship of overweight and insulin reserve in T1D new-onsets over time. Linear mixed 
models are an appropriate method to analyze correlated longitudinal data. Since C-peptide values 
are right skewed in this population, the performance of the estimates for predictors may not be 
robust enough. However, since the primary goal of this study was to model the course of the C-
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peptide across time, the results given by linear mixed models could give some useful reference 
here. In order to improve the goodness-of-fit of the models, the same linear mixed models were 
fitted using log-transformation C-peptide and log-ratio of C-peptide to onset as primary 
endpoints. The effects of overweight at onset showed the same pattern as has been discussed 
earlier, even though the overweight was no longer a statistically significant predictor (Appendix 
A7). Moreover, the Pearson residuals plots showed better fit using log-transformed C-peptide 
than the untransformed values of C-peptide (Appendix A7), but the interpretation of the 
transformed data is less clear. Additionally, in the current study, C-peptide levels at diagnosis 
were not included in the models because of the non-linear changes from onset to 3 months, and 
then from 3 months and beyond.  
As there is still no cure for T1D, it is important to identify characteristics related to 
prolong preservation of insulin production in patients. Clinically, the diagnosis of T1D was 
followed by a short remission period at 3 months after being placed in insulin therapy. 
Maintaining or extending the honeymoon period could delay or prevent T1D children from 
developing severe complications. In this study, the overweight children had a higher level of 
insulin reserve than the non-overweight children across the entire two-year follow-up, especially 
in the honeymoon phase. These findings may well suggest that the overweight status at onset 
may be informative in developing effective interventions targeting on overweight patients with 
higher C-peptide to prolong their preservation of residual function of pancreas β cells.  
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APPENDIX A: SUPPLEMENTARY RESULTS 
A.1 SUBJECTS AND FOLLOW-UPS
Table 16. Summary of duplicate records in each follow-up 
Study windowΔ # participants # single record # multiple records* 
Onset 198 42 156 
3-month 194 193 1 
6-month 176 165 11 
12-month 181 169 12 
18-month 168 152 16 
24-month 169 158 11 
* Some participants have more than 2 records in each study window.
Δ This study just concerns up to 2-year follow-up.
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Table 17. Demographic and clinical characteristics of subjects having 3 autoantibodies measured at baseline 
(N=11) 
 
Characteristics Subjects with 3 autoantibodies measured 
at baseline (N=11) 
Demographic  
Age at diagnosis, yrs 8.4 ± 3.8 
Age group, yrs, n (%)  
       0-4 18 (10.71) 
       5-9 68 (40.48) 
       10-14 69 (41.07) 
       ≥ 15 13 (7.74) 
Gender, n (%)  
       Male 8 (72.73) 
       Female 3 (27.27) 
Race, n (%)  
       White 11 (100) 
       Black 0 
       Other 0 
BMI at onset, kg/m2 18.26 ± 6.21 
BMI at 3 months, kg/m2 19.48 ± 4.56 
BMI % at onset 48.99 ± 38.67 
BMI % at 3 months 72.80 ± 25.59 
BMI z-score at onset 0.02 ± 1.70 
BMI z-score at 3 months 0.86 ± 0.94 
Clinical  
HbA1c at onset 11.75 ± 2.51 
HbA1c at 3 months 7.35 ± 0.83 
IDAA1c at 3 months 9.61 ± 1.59a 
Positive antibodies at baseline, n (%)  
       0 1 (9.09) 
       1 5 (45.45) 
       2 3 (27.27) 
       3 2 (18.18) 
Autoantibodies at baseline, n (%)  
       + IAA 0 
       + IA2 4 (36.36) 
       + GAD 5 (45.45) 
       + ICA human 8 (72.73) 
C-peptide, ng/mL  
       < 14 days 0.57 [0.50, 0.81] 
       3 months 0.88 [0.71, 2.38]a 
       6 months 0.85 [0.60, 1.45]b 
       12 months 0.47 [0.31, 1.00]b 
       18 months 0.40 [0.10, 0.88]c 
       24 months 0.10 [0.10, 0.10]d 
* Data are mean ± SD or median [IQR] unless otherwise noted.  
a Based on 10 subjects. b Based on 9 subjects. c Based on 6 subjects. d Based on 8 subjects. 
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Table 18. Combinations of positive autoantibodies at baseline of study subjects (N=168) 
 Positive Abs combination at baseline N (%) 
All negative  16 (100) 16 (9.52) 
    
One positive IA2 2 (15.38) 
13 (7.74)  IAA 2 (15.38)  ICA human 4 (30.77) 
 GAD 5 (38.46) 
    
Two positive IA2 and IAA 1 (3.70) 
27 (16.07) 
 IA2 and ICA human 8 (29.63) 
 IA2 and GAD 2 (7.41) 
 IA2 and ZnT8A 1 (3.70) 
 IAA and ICA human 2 (7.41) 
 ICA human and GAD 6 (22.22) 
 ICA human and ZnT8A 5 (18.52) 
 GAD and ZnT8A 2 (7.41) 
    
Three positive IA2, IAA, and ICA human 3 (5.56) 
54 (32.14) 
 IA2, ICA human, and GAD 13 (24.07) 
 IA2, ICA human, and ZnT8A 27 (50) 
 IA2, GAD, and ZnT8A 1 (1.85) 
 IAA, ICA human, and ZnT8A 2 (3.70) 
 ICA human, GAD, and ZnT8A 8 (14.81) 
    
Four positive IA2, IAA, ICA human, and GAD 4 (8.16) 
49(29.17) 
 IA2, IAA, ICA human, and ZnT8A 6 (12.24) 
 IA2, IAA, GAD, and ZnT8A 1 (2.04) 
 IA2, ICA human, GAD, and ZnT8A 37 (75.51) 
 IAA, ICA human, GAD, and ZnT8A 1 (2.04) 
    
Five positive IA2, IAA, ICA human, GAD, and ZnT8A 9 (100) 9 (5.36) 
    
Total  168  168 (100) 
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A.2 C-PEPTIDE OF EACH FOLLOW-UP 
Table 19. Sixteen follow-up patterns for C-peptide (N=168) 
<14 days 3 months 6 months 12 months 18 months 24 months N (%) 
X X X X X X 63 (37.50) 
X X X X X . 21 (12.50) 
X X X X . X 21 (12.50) 
X X X X . . 3 (1.79) 
X X X . X X 14 (8.33) 
X X X . X . 2 (1.19) 
X X X . . X 5 (2.98) 
X X . X X X 16 (9.52) 
X X . X X . 5 (2.98) 
X X . X . X 3 (1.79) 
X X . . X X 4 (2.38) 
X . X X X X 3 (1.79) 
X . X X X . 2 (1.19) 
X . X X . X 3 (1.79) 
X . X . X X 2 (1.19) 
X . . X X X 1 (0.60) 
* X indicates that there is a clinical record for that follow-up.  
Table 20. The rate (exact) of change of fasting C-peptide of each follow-up visit 
Visits N Mean ± SD Median [IQR] P value 
A. The rate of change from onset 
3 months 157 0.52 ± 0.61 0.37 [0.08, 0.89] <0.0001c 
6 months 139 0.17 ± 0.25 0.10 [0, 0.28] <0.0001c 
12 months 141 0.03 ± 0.09 0.01 [-0.02, 0.06] 0.15c 
18 months 133 0.01 ± 0.06 -0.01 [-0.02, 0.03] 0.22c 
24 months 135 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.0001c 
B. The rate of change from 3 months 
6 months 129 -0.07 ± 0.42 -0.08 [-0.28, 0.11] <0.01b 
12 months 132 -0.09 ± 0.15 -0.07 [-0.15, -0.01] <0.0001b 
18 months 125 -0.06 ± 0.09 -0.05 [-0.12, -0.01] <0.0001a 
24 months 126 -0.06 ± 0.06 -0.05 [-0.11, -0.02] <0.0001b 
C. The rate of change from each follow-up to subsequence 
Onset - 3 months 157 0.52 ± 0.61 0.37 [0.08, 0.89] <0.0001c 
3 months - 6 months 129 -0.07 ± 0.42 -0.08 [-0.28, 0.11] <0.01b 
6 months - 12 months 116 -0.09 ± 0.15 -0.06 [-0.17, -0.01] <0.0001b 
12 months - 18 months 111 -0.03 ± 0.11 -0.03 [-0.07, 0] <0.0001b 
18 months - 24 months 103 -0.05 ± 0.09 -0.02 [-0.08, 0] <0.0001c 
* Values are calculated by the change in subject / the difference of exact days since diagnosis between two follow 
up visits in months, in ng/mL/month. a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test. 
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Figure 13. The rate of change (exact) of C-peptide 
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A.3 C-PEPTIDE BY OVERWEIGHT STATUS AT ONSET 
Table 21. The rate of change (exact) of C-peptide among overweight and non-overweight subjects at onset (N=168) 
Visits Overweight at onset   Non-overweight at onset P value* N Mean ± SD Median [IQR] P value N Mean ± SD Median [IQR] P value 
A. Change of C-peptide from onset 
3 months 33 0.66 ± 0.86 0.49 [-0.08, 0.89] 0.04c 119 0.49 ± 0.52 0.36 [0.10, 0.92] <0.0001b 0.77 
6 months 31 0.21 ± 0.29 0.13 [0, 0.49] <0.001b 103 0.16 ± 0.23 0.10 [0.01, 0.28] <0.0001c 0.64 
12 months 29 0.04 ± 0.09 0.01 [-0.01, 0.11] 0.26c 108 0.03 ± 0.09 0.01 [-0.02, 0.06] 0.25c 0.63 
18 months 26 0.03 ± 0.06 0.01 [-0.02, 0.06] 0.06b 103 0.01 ± 0.05 -0.01 [-0.02, 0.02] 0.11c 0.14 
24 months 31 -0.01 ± 0.03 -0.02 [-0.03, 0] <0.01c 100 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.0001c 0.32 
B. Change of C-peptide from 3 months 
6 months 28 -0.09 ± 0.53 -0.13 [-0.31, 0.15] 0.35 a 96 -0.06 ± 0.39 -0.08 [-0.28, 0.12] 0.02 c 0.73 
12 months 27 -0.14 ± 0.21 -0.11 [-0.28, -0.01] <0.01a 101 -0.07 ± 0.13 -0.06 [-0.13, -0.01] <0.0001b 0.17 
18 months 25 -0.07 ± 0.13 -0.05 [-0.15, -0.01] 0.01 a 96 -0.05 ± 0.08 -0.05 [-0.11, -0.01] <0.0001b 0.75 
24 months 28 -0.08 ± 0.09 -0.07 [-0.13, -0.01] 0.0001a 94 -0.06 ± 0.05 -0.05 [-0.10, -0.02] <0.0001a 0.35a 
C. Change of C-peptide from each follow-up to subsequence 
3 months 33 0.66 ± 0.86 0.49 [-0.08, 0.89] 0.04 c 119 0.49 ± 0.52 0.36 [0.10, 0.92] <0.0001b 0.69 
6 months 28 -0.09 ± 0.53 -0.13 [-0.31, 0.15] 0.35 a 96 -0.06 ± 0.39 -0.08 [-0.28, 0.12] 0.02 c 0.58 
12 months 24 -0.13 ± 0.22 -0.07 [-0.24, -0.03] <0.01c 88 -0.08 ± 0.13 -0.06 [-0.16, -0.01] <0.0001b 0.35 
18 months 21 -0.02 ± 0.08 0 [-0.06, 0.01] 0.23 a 87 -0.03 ± 0.12 -0.03 [-0.07, 0] <0.0001b 0.61 
24 months 22 -0.10 ± 0.12 -0.06 [-0.15, 0] 0.001c 78 -0.04 ± 0.08 -0.01 [-0.05, 0] <0.0001c 0.02 
* Values are calculated by the change in subject / the difference of exact days since diagnosis between two follow up visits in months, in ng/mL/month. P values 
are obtained from Wilcoxon-Mann-Whitney test for two independent samples unless otherwise noted. a Based on t-test. b Based on Wilcoxon signed rank test. c 
Based on sign test. 
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Figure 14. The rate of change (window) of C-peptide between two visits among overweight and non-
overweight subjects at onset 
 
Left three are the trajectory of mean value of the rate of change of C-peptide from onset, 3 months, and previous 
visit, respectively. Right three are the trajectory of median value of the rate of change of C-peptide from onset, 3 
months, and previous visit. 
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A.4 C-PEPTIDE BY OVERWEIGHT STATUS AT ONSET AND 3 MONTHS 
Table 22. The rate of change (window) of fasting C-peptide for each follow-up visit among overweight status 
at onset and 3-month visit (N=168) 
 
A. The rate of change of C-peptide from onset 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
Within Between 
Between 
(exclude 
O - N) 
3 months 
O - O 29 0.44 ± 0.61 0.31 [-0.10, 0.71] 0.14c 
0.19 0.82 O - N 3 1.27 ± 0.94 1.10 [0.43, 2.29] 0.14
a 
N - O 27 0.32 ± 0.33 0.22 [0.04, 0.65] <0.0001b 
N - N 91 0.37 ± 0.38 0.29 [0.09, 0.66] <0.0001b 
6 months 
O - O 24 0.19 ± 0.28 0.09 [-0.02, 0.47] <0.01b 
0.89 0.74 O - N 4 0.16 ± 0.22 0.15 [0.01, 0.31] 0.24
a 
N - O 23 0.13 ± 0.22 0.05 [0, 0.22] 0.02c 
N - N 79 0.15 ± 0.20 0.11 [0.02, 0.25] <0.0001c 
12 months 
O - O 23 0.04 ± 0.11 0.01 [-0.03, 0.13] 0.68c 
0.88 0.98 O - N 3 0.05 ± 0.05 0.04 [-0.01, 0.10] 0.28
a 
N - O 22 0.05 ± 0.13 0 [-0.03, 0.08] 1.00c 
N - N 84 0.03 ± 0.08 0.01 [-0.02, 0.06] 0.01b 
18 months 
O - O 22 0.03 ± 0.07 0 [-0.02, 0.07] 0.83c 
0.15 0.64 O - N 3 0.07 ± 0.04 0.07 [0.03, 0.11] 0.10
a 
N - O 24 0.02 ± 0.08 -0.02 [-0.02, 0.02] 0.54c 
N - N 77 0 ± 0.04 -0.01 [-0.02, 0.02] 0.11c 
24 months 
O - O 24 -0.01 ± 0.04 -0.02 [-0.03, 0.01] 0.02c 
0.76 0.56 O - N 4 -0.02 ± 0.03 -0.01 [-0.03, 0] 0.13
c 
N - O 22 0 ± 0.04 -0.02 [-0.02, 0] 0.02c 
N - N 77 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.0001c 
B. The rate of change of C-peptide from 3-month visit 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
Within Between 
Between 
(exclude 
O - N) 
6 months 
O - O 24 -0.03 ± 0.48 -0.10 [-0.32, 0.25] 0.79a 
0.18 0.87 O - N 3 -0.79 ± 0.61 -0.74 [-1.42, -0.20] 0.16
a 
N - O 23 -0.03 ± 0.44 -0.07 [-0.17, 0.18] 0.78a 
N - N 73 -0.07 ± 0.42 -0.10 [-0.29, 0.13] 0.10c 
12 months 
O - O 23 -0.12 ± 0.20 -0.09 [-0.25, 0.01] 0.01a 
0.06 0.32 O - N 3 -0.36 ± 0.24 -0.31 [-0.62, -0.15] 0.12
a 
N - O 22 -0.04 ± 0.17 -0.04 [-0.12, 0.06] 0.35a 
N - N 78 -0.08 ± 0.13 -0.08 [-0.15, -0.02] <0.0001b 
18 months 
O - O 22 -0.05 ± 0.13 -0.05 [-0.14, 0.06] 0.07a 
0.08 0.41 O - N 2 -0.26 ± 0.10 -0.26 [-0.33, -0.19] 0.17
a 
N - O 24 -0.04 ± 0.09 -0.03 [-0.07, 0] 0.06a 
N - N 71 -0.06 ± 0.08 -0.06 [-0.13, -0.02] <0.0001a 
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Table 21. The rate of change (window) of fasting C-peptide for each follow-up visit among overweight status at 
onset and 3-month visit (N=168) (continue) 
 
24 months 
O - O 24 -0.06 ± 0.08 -0.06 [-0.12, -0.01] 0.001a 
0.16 0.66 O - N 3 -0.19 ± 0.13 -0.16 [-0.33, -0.07] 0.13
a 
N - O 22 -0.05 ± 0.05 -0.04 [-0.10, -0.02] <0.001a 
N - N 71 -0.07 ± 0.06 -0.05 [-0.11, -0.03] <0.0001a 
C. The rate of change of C-peptide from each visit to subsequence 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
Within Between 
Between 
(exclude 
O - N) 
3 months 
O - O 29 0.44 ± 0.61 0.31 [-0.10, 0.71] 0.14c 
0.19 0.82 O - N 3 1.27 ± 0.94 1.10 [0.43, 2.29] 0.14
a 
N - O 27 0.32 ± 0.33 0.22 [0.04, 0.65] <0.0001b 
N - N 91 0.37 ± 0.38 0.29 [0.09, 0.66] <0.0001b 
6 months 
O - O 24 -0.03 ± 0.48 -0.10 [-0.32, 0.25] 0.79a 
0.18 0.87 O - N 3 -0.79 ± 0.61 -0.74 [-1.42, -0.20] 0.16
a 
N - O 23 -0.03 ± 0.44 -0.07 [-0.17, 0.18] 0.78a 
N - N 73 -0.07 ± 0.42 -0.10 [-0.29, 0.13] 0.10c 
12 months 
O - O 18 -0.12 ± 0.19 -0.06 [-0.25, -0.02] 0.01a 
0.54 0.82 O - N 3 -0.15 ± 0.07 -0.13 [-0.23, -0.10] 0.06
a 
N - O 19 -0.08 ± 0.10 -0.07 [-0.17, -0.01] <0.01a 
N - N 68 -0.08 ± 0.15 -0.06 [-0.16, -0.01] <0.0001b 
18 months 
O - O 18 -0.03 ± 0.10 -0.03 [-0.09, 0.01] 0.27a 
0.26 0.61 O - N 2 0.06 ± 0.08 0.06 [0, 0.11] 0.49
a 
N - O 20 -0.04 ± 0.15 0 [-0.05, 0.01] 0.24c 
N - N 65 -0.04 ± 0.12 -0.03 [-0.08, 0] <0.0001b 
24 months 
O - O 18 -0.08 ± 0.11 -0.04 [-0.14, 0] 0.01c 
0.03 0.32 O - N 3 -0.28 ± 0.17 -0.32 [-0.43, -0.10] 0.10
a 
N - O 20 -0.05 ± 0.12 0 [-0.08, 0] 0.09c 
N - N 57 -0.04 ± 0.06 -0.01 [-0.05, 0] <0.0001c 
*Values are calculated by the change in subject / t the length of window between two follow-ups in months, in 
ng/mL/month. Between P values are obtained from Kruskal-Wallis test. Within P values are obtained from paired 
sample test. a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test. 
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Figure 15. Trajectory plot for mean and median rate (window) of change of C-peptide by overweight status at 
onset and 3 months 
 
Left three are the trajectory of mean value of the rate of change of C-peptide from onset, 3 months, and previous 
visit, respectively. Right three are the trajectory of median value of the rate of change of C-peptide from onset, 3 
months, and previous visit. Values are calculated by the change in subject / the length of window between two 
follow-ups in months, in ng/mL/month. 
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Table 23. The rate of change (exact) of fasting C-peptide for each follow-up visit among overweight status at 
onset and 3-month visit (N=168) 
 
A. The rate of change of C-peptide from onset 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
Within Between 
Between 
(exclude 
O - N) 
3 months 
O - O 29 0.57 ± 0.80 0.40 [-0.12, 0.88] 0.14c 
0.23 0.80 O - N 3 1.59 ± 1.15 1.50 [0.48, 2.78] 0.14
a 
N - O 27 0.46 ± 0.48 0.26 [0.06, 0.94] <0.0001b 
N - N 91 0.50 ± 0.54 0.37 [0.12, 0.92] <0.0001b 
6 months 
O - O 24 0.21 ± 0.30 0.11 [-0.02, 0.47] 0.06b 
0.92 0.78 O - N 4 0.16 ± 0.26 0.15 [-0.01, 0.34] 0.29
a 
N - O 23 0.16 ± 0.27 0.06 [0, 0.23] 0.02c 
N - N 79 0.16 ± 0.22 0.12 [0.02, 0.29] <0.0001c 
12 months 
O - O 23 0.04 ± 0.10 0.01 [-0.03, 0.13] 0.68c 
0.87 0.99 O - N 3 0.05 ± 0.06 0.04 [-0.01, 0.11] 0.28
a 
N - O 22 0.05 ± 0.13 0 [-0.03, 0.07] 1.00c 
N - N 84 0.03 ± 0.08 0.01 [-0.02, 0.06] 0.19c 
18 months 
O - O 22 0.03 ± 0.07 0 [-0.02, 0.06] 0.83c 
0.15 0.64 O - N 3 0.07 ± 0.04 0.06 [0.03, 0.11] 0.10
a 
N - O 24 0.02 ± 0.08 -0.02 [-0.02, 0.02] 0.54c 
N - N 77 0 ± 0.04 -0.01 [-0.02, 0.02] 0.11c 
24 months 
O - O 24 -0.01 ± 0.03 -0.02 [-0.03, 0] 0.02c 
0.72 0.50 O - N 4 -0.02 ± 0.03 -0.01 [-0.03, 0] 0.13
c 
N - O 22 0 ± 0.04 -0.02 [-0.02, 0] 0.02c 
N - N 77 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.0001c 
B. The rate of change of C-peptide from 3-month visit 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
Within Between 
Between 
(exclude 
O - N) 
6 months 
O - O 24 -0.01 ± 0.46 -0.08 [-0.26, 0.21] 0.95a 
0.21 0.82 O - N 3 -0.76 ± 0.70 -0.60 [-1.52, -0.16] 0.20
a 
N - O 23 -0.02 ± 0.46 -0.07 [-0.17, 0.16] 0.85a 
N - N 73 -0.07 ± 0.37 -0.09 [-0.29, 0.10] 0.10c 
12 months 
O - O 23 -0.11 ± 0.20 -0.07 [-0.25, 0.01] 0.01a 
0.06 0.32 O - N 3 -0.36 ± 0.27 -0.29 [-0.65, -0.13] 0.14
a 
N - O 22 -0.04 ± 0.17 -0.03 [-0.11, 0.07] 0.31a 
N - N 78 -0.08 ± 0.12 -0.07 [-0.14, -0.02] <0.0001b 
18 months 
O - O 22 -0.05 ± 0.12 -0.05 [-0.12, 0.05] 0.07a 
0.08 0.40 O - N 2 -0.25 ± 0.11 -0.25 [-0.33, -0.18] 0.19
a 
N - O 24 -0.04 ± 0.09 -0.03 [-0.07, 0] 0.05a 
N - N 71 -0.06 ± 0.08 -0.06 [-0.12, -0.02] <0.0001a 
24 months 
O - O 24 -0.06 ± 0.08 -0.06 [-0.12, -0.01] 0.001a 
0.15 0.67 O - N 3 -0.18 ± 0.12 -0.16 [-0.31, -0.08] 0.12
a 
N - O 22 -0.05 ± 0.05 -0.04 [-0.10, -0.02] <0.001a 
N - N 71 -0.06 ± 0.05 -0.05 [-0.11, -0.03] <0.0001a 
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Table 22. The rate of change (exact) of fasting C-peptide for each follow-up visit among overweight status at onset 
and 3-month visit (N=168) (continue) 
 
C. The rate of change of C-peptide from each visit to subsequence 
Visits 
Overweight 
status at onset 
and 3 months 
N Mean ± SD Median [IQR] 
P value 
Within Between 
Between 
(exclude 
O - N) 
3 months 
O - O 29 0.57 ± 0.80 0.40 [-0.12, 0.88] 0.14c 
0.23 0.80 O - N 3 1.59 ± 1.15 1.50 [0.48, 2.78] 0.14
a 
N - O 27 0.46 ± 0.48 0.26 [0.06, 0.94] <0.0001b 
N - N 91 0.50 ± 0.54 0.37 [0.12, 0.92] <0.0001b 
6 months 
O - O 24 -0.01 ± 0.46 -0.08 [-0.26, 0.21] 0.95a 
0.21 0.82 O - N 3 -0.76 ± 0.70 -0.60 [-1.52, -0.16] 0.20
a 
N - O 23 -0.02 ± 0.46 -0.07 [-0.17, 0.16] 0.85a 
N - N 73 -0.07 ± 0.37 -0.09 [-0.29, 0.10] 0.10c 
12 months 
O - O 18 -0.14 ± 0.24 -0.06 [-0.24, -0.02] 0.01c 
0.51 0.84 O - N 3 -0.15 ± 0.07 -0.12 [-0.23, -0.10] 0.07
a 
N - O 19 -0.07 ± 0.09 -0.07 [-0.16, -0.01] <0.01a 
N - N 68 -0.08 ± 0.14 -0.06 [-0.16, -0.01] <0.0001b 
18 months 
O - O 18 -0.03 ± 0.08 -0.02 [-0.08, 0.01] 0.17a 
0.24 0.58 O - N 2 0.05 ± 0.08 0.05 [0, 0.11] 0.49
a 
N - O 20 -0.03 ± 0.12 0 [-0.05, 0.01] 0.10b 
N - N 65 -0.03 ± 0.11 -0.04 [-0.07, 0] <0.0001b 
24 months 
O - O 18 -0.08 ± 0.10 -0.05 [-0.14, 0] 0.01c 
0.03 0.27 O - N 3 -0.24 ± 0.13 -0.27 [-0.36, -0.10] 0.08
a 
N - O 20 -0.04 ± 0.12 -0.01 [-0.08, 0] 0.04b 
N - N 57 -0.04 ± 0.06 -0.02 [-0.05, 0] <0.0001c 
*Values are calculated by the change in subject / the difference of exact days since diagnosis between two follow up 
visits in months, in ng/mL/month. Between P values are obtained from Kruskal-Wallis test. Within P values are 
obtained from paired sample test. a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test. 
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Figure 16. Trajectory plot for mean and median rate (exact) of change of C-peptide by overweight status at 
onset and 3 months 
 
Left three are the trajectory of mean value of the rate of change of C-peptide from onset, 3 months, and previous 
visit, respectively. Right three are the trajectory of median value of the rate of change of C-peptide from onset, 3 
months, and previous visit. Values are calculated by the change in subject / the difference of exact days since 
diagnosis between two follow up visits in months, in ng/mL/month. 
 
 
 
55 
A.5 C-PEPTIDE BY NUMBER OF POSITIVE AUTOANTIBODIES AT BASELINE  
Table 24. The rate (window) of change of C-peptide among subjects with different number of positive 
antibodies at baseline (N=168) 
 
A. Change of C-peptide from onset 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] 
P value 
Within Between 
3 months 
0 15 0.38 ± 0.58 0.21 [0, 0.46] 0.12c 
0.31 
1 11 0.31 ± 0.40 0.22 [0.03, 0.47] 0.03a 
2 26 0.52 ± 0.42 0.55 [0.11, 0.85] <0.0001a 
3 51 0.32 ± 0.41 0.22 [0.03, 0.51] <0.001c 
4 or 5 54 0.40 ± 0.47 0.29 [0.07, 0.69] <0.0001c 
6 months 
0 11 0.20 ± 0.20 0.16 [0.03, 0.33] <0.01a 
0.43 
1 11 0.22 ± 0.24 0.16 [0.05, 0.25] 0.001c 
2 25 0.19 ± 0.23 0.15 [0, 0.31] <0.001a 
3 46 0.15 ± 0.24 0.07 [0.02, 0.18] <0.001c 
4 or 5 46 0.12 ± 0.20 0.07 [-0.05, 0.26] <0.001b 
12 months 
0 14 0.06 ± 0.08 0.08 [-0.02, 0.14] 0.04b 
0.24 
1 12 0.07 ± 0.12 0.02 [0, 0.11] 0.15c 
2 26 0.04 ± 0.08 0.01 [-0.03, 0.08] 0.56c 
3 41 0.02 ± 0.10 0 [-0.03, 0.05] 1.00c 
4 or 5 48 0.02 ± 0.08 0.01 [-0.03, 0.04] 0.56c 
18 months 
0 12 0.04 ± 0.05 0.03 [0, 0.07] 0.02a 
0.04 
1 9 0.04 ± 0.04 0.03 [0, 0.08] 0.04a 
2 21 0.02 ± 0.08 -0.02 [-0.02, 0.03] 0.66c 
3 44 0.01 ± 0.06 -0.01 [-0.02, 0.02] 0.10c 
4 or 5 47 0 ± 0.04 -0.01 [-0.02, 0.02] 0.14c 
24 months 
0 11 0 ± 0.03 0 [-0.02, 0.02] 0.74a 
0.33 
1 13 0.01 ± 0.04 0 [-0.02, 0.03] 1.00c 
2 22 0 ± 0.04 -0.02 [-0.02, 0] 0.02c 
3 43 -0.01 ± 0.03 -0.02 [-0.02, -0.01] <0.0001c 
4 or 5 46 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.001c 
B. Change of C-peptide from 3-month visit 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] 
P value 
Within Between 
6 months 
0 10 0.08 ± 0.56 0.08 [-0.17, 0.15] 0.64a 
0.33 
1 9 0.13 ± 0.44 0.03 [-0.17, 0.40] 0.39a 
2 24 -0.14 ± 0.39 -0.16 [-0.33, 0.01] 0.09a 
3 44 -0.05 ± 0.40 -0.13 [-0.22, 0.15] 0.10c 
4 or 5 42 -0.14 ± 0.48 -0.09 [-0.43, 0.13] 0.07a 
12 months 
0 13 -0.06 ± 0.21 -0.03 [-0.12, 0.07] 0.30a 
0.38 
1 11 -0.01 ± 0.16 -0.03 [-0.11, 0.05] 0.23c 
2 25 -0.12 ± 0.14 -0.09 [-0.20, -0.02] <0.001a 
3 38 -0.08 ± 0.16 -0.07 [-0.13, -0.03] <0.01a 
4 or 5 45 -0.11 ± 0.16 -0.07 [-0.17, -0.03] <0.0001b 
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Table 23. The rate (window) of change of C-peptide among subjects with different number of positive antibodies 
at baseline (N=168) (continue) 
 
18 months 
0 11 -0.04 ± 0.13 -0.07 [-0.10, 0.01] 0.27a 
0.06 
1 8 0 ± 0.07 0.02 [-0.04, 0.04] 0.94a 
2 20 -0.08 ± 0.11 -0.09 [-0.15, -0.03] <0.01a 
3 42 -0.04 ± 0.08 -0.05 [-0.10, -0.01] <0.001a 
4 or 5 44 -0.08 ± 0.10 -0.07 [-0.14, -0.03] <0.0001a 
24 months 
0 11 -0.03 ± 0.06 -0.05 [-0.05, -0.01] 0.07c 
0.22 
1 11 -0.04 ± 0.07 -0.02 [-0.09, 0.02] 0.12a 
2 21 -0.09 ± 0.07 -0.08 [-0.13, -0.03] <0.0001a 
3 40 -0.06 ± 0.06 -0.05 [-0.10, -0.02] <0.0001a 
4 or 5 43 -0.07 ± 0.07 -0.05 [-0.12, -0.02] <0.0001c 
C. Change of C-peptide from each visit to subsequence 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] 
P value 
Within Between 
3 months 
0 15 0.38 ± 0.58 0.21 [0, 0.46] 0.12c 
0.31 
1 11 0.31 ± 0.40 0.22 [0.03, 0.47] 0.03a 
2 26 0.52 ± 0.42 0.55 [0.11, 0.85] <0.0001a 
3 51 0.32 ± 0.41 0.22 [0.03, 0.51] <0.0001c 
4 or 5 54 0.40 ± 0.47 0.29 [0.07, 0.69] <0.0001c 
6 months 
0 10 -0.06 ± 0.21 -0.03 [-0.12, 0.07] 0.64a 
0.33 
1 9 -0.01 ± 0.16 -0.03 [-0.11, 0.05] 0.39a 
2 24 -0.12 ± 0.14 -0.09 [-0.20, -0.02] 0.09a 
3 44 -0.08 ± 0.16 -0.07 [-0.13, -0.03] 0.10c 
4 or 5 42 -0.11 ± 0.16 -0.07 [-0.17, -0.03] 0.07a 
12 months 
0 10 -0.07 ± 0.12 -0.09 [-0.17, 0.01] 0.10a 
0.95 
1 10 -0.06 ± 0.11 -0.05 [-0.13, -0.01] 0.13a 
2 24 -0.11 ± 0.13 -0.07 [-0.17, -0.01] <0.001c 
3 36 -0.10 ± 0.14 -0.06 [-0.18, -0.03] <0.0001b 
4 or 5 36 -0.09 ± 0.17 -0.06 [-0.20, -0.01] <0.01a 
18 months 
0 10 -0.03 ± 0.17 -0.07 [-0.11, 0.09] 0.58a 
0.93 
1 8 -0.05 ± 0.23 -0.03 [-0.09, 0.06] 0.59a 
2 20 -0.03 ± 0.12 -0.04 [-0.07, 0] 0.04b 
3 34 -0.03 ± 0.05 -0.03 [-0.06, 0] 0.001a 
4 or 5 39 -0.03 ± 0.14 -0.02 [-0.09, 0] 0.02b 
24 months 
0 8 -0.06 ± 0.08 0 [-0.14, 0] 0.19c 
0.19 
1 9 -0.05 ± 0.10 -0.06 [-0.08, -0.03] 0.16a 
2 17 -0.11 ± 0.14 -0.06 [-0.11, 0] <0.001c 
3 33 -0.04 ± 0.06 -0.01 [-0.04, 0] <0.01c 
4 or 5 36 -0.05 ± 0.10 -0.02 [-0.05, 0] <0.0001c 
*Values are calculated by the change in subject / the length of window between two follow-ups in months, in 
ng/mL/month. Between P values are obtained from Kruskal-Wallis test. Within P values are obtained from paired 
sample test. a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test. 
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Figure 17. Trajectory plot for mean and median rate (window) of change of C-peptide for different number 
of positive autoantibodies at baseline 
 
Left three are the trajectory of mean value of the rate of change of C-peptide from onset, 3 months, and previous 
visit, respectively. Right three are the trajectory of median value of the rate of change of C-peptide from onset, 3 
months, and previous visit. Values are calculated by the change in subject / the length of window between two 
follow-ups in months, in ng/mL/month. 
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Table 25. The rate (exact) of change of C-peptide for each follow-up visit among subjects with different 
number of positive antibodies at baseline (N=168) 
 
A. Change of C-peptide from onset 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] 
P value 
Within Between 
3 months 
0 15 0.50 ± 0.73 0.29 [0, 0.58] 0.12c 
0.31 
1 11 0.37 ± 0.40 0.31 [0.05, 0.58] 0.01a 
2 26 0.74 ± 0.64 0.72 [0.16, 1.21] <0.0001a 
3 51 0.45 ± 0.60 0.28 [0.04, 0.88] <0.001c 
4 or 5 54 0.52 ± 0.59 0.37 [0.09, 0.84] <0.0001c 
6 months 
0 11 0.23 ± 0.23 0.18 [0.03, 0.43] <0.01a 
0.40 
1 11 0.23 ± 0.25 0.15 [0.06, 0.29] 0.001c 
2 25 0.22 ± 0.28 0.16 [0, 0.35] <0.001a 
3 46 0.17 ± 0.26 0.08 [0.02, 0.20] <0.001c 
4 or 5 46 0.13 ± 0.20 0.07 [-0.05, 0.29] <0.001b 
12 months 
0 14 0.07 ± 0.09 0.08 [-0.01, 0.14] 0.01a 
0.23 
1 12 0.07 ± 0.13 0.02 [0, 0.11] 0.15c 
2 26 0.04 ± 0.09 0.01 [-0.03, 0.07] 0.56c 
3 41 0.02 ± 0.09 0 [-0.03, 0.05] 1.00c 
4 or 5 48 0.02 ± 0.08 0.01 [-0.03, 0.04] 0.56c 
18 months 
0 12 0.04 ± 0.05 0.03 [0, 0.07] 0.02a 
0.05 
1 9 0.04 ± 0.04 0.04 [0, 0.09] 0.03a 
2 21 0.02 ± 0.08 -0.01 [-0.02, 0.03] 0.66c 
3 44 0.01 ± 0.06 -0.01 [-0.02, 0.02] 0.10c 
4 or 5 47 0 ± 0.04 -0.01 [-0.02, 0.02] 0.14c 
24 months 
0 11 0 ± 0.03 0 [-0.02, 0.02] 0.79a 
0.26 
1 13 0.01 ± 0.04 0 [-0.02, 0.03] 1.00c 
2 22 0 ± 0.04 -0.02 [-0.02, 0] 0.02c 
3 43 -0.01 ± 0.03 -0.02 [-0.02, -0.01] <0.0001c 
4 or 5 46 -0.01 ± 0.03 -0.02 [-0.02, 0] <0.001c 
B. Change of C-peptide from 3-month visit 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] 
P value 
Within Between 
6 months 
0 11 0.09 ± 0.55 0.07 [-0.15, 0.16] 0.63a 
0.27 
1 11 0.13 ± 0.46 0.04 [-0.16, 0.30] 0.40a 
2 25 -0.13 ± 0.40 -0.14 [-0.32, 0.01] 0.14a 
3 46 -0.06 ± 0.38 -0.08 [-0.22, 0.14] 0.10c 
4 or 5 46 -0.12 ± 0.42 -0.09 [-0.32, 0.09] 0.07a 
12 months 
0 14 -0.06 ± 0.20 -0.03 [-0.11, 0.07] 0.32a 
0.41 
1 12 -0.01 ± 0.15 -0.03 [-0.12, 0.04] 0.23c 
2 26 -0.11 ± 0.13 -0.09 [-0.21, -0.03] <0.001a 
3 41 -0.07 ± 0.15 -0.07 [-0.12, -0.03] <0.01a 
4 or 5 48 -0.11 ± 0.15 -0.07 [-0.17, -0.02] <0.0001c 
18 months 
0 12 -0.04 ± 0.11 -0.06 [-0.10, 0.01] 0.24a 
0.06 
1 9 0 ± 0.07 0.02 [-0.04, 0.04] 0.95a 
2 21 -0.08 ± 0.10 -0.08 [-0.15, -0.03] <0.01a 
3 44 -0.04 ± 0.08 -0.05 [-0.09, -0.01] <0.001a 
4 or 5 47 -0.07 ± 0.09 -0.06 [-0.13, -0.02] <0.0001a 
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Table 24. The rate (exact) of change of C-peptide for each follow-up visit among subjects with different number 
of positive antibodies at baseline (N=168) (continue) 
 
24 months 
0 11 -0.03 ± 0.05 -0.05 [-0.05, -0.01] 0.07c 
0.21 
1 13 -0.03 ± 0.07 -0.02 [-0.09, 0.02] 0.13a 
2 22 -0.08 ± 0.06 -0.07 [-0.13, -0.03] <0.0001a 
3 43 -0.06 ± 0.06 -0.05 [-0.10, -0.02] <0.0001a 
4 or 5 46 -0.07 ± 0.07 -0.05 [-0.11, -0.02] <0.0001c 
C. Change of C-peptide from each visit to subsequence 
Visits # positive Abs at baseline N Mean ± SD Median [IQR] 
P value 
Within Between 
3 months 
0 15 0.50 ± 0.73 0.29 [0, 0.58] 0.12c 
0.31 
1 11 0.37 ± 0.40 0.31 [0.05, 0.58] 0.01a 
2 26 0.74 ± 0.64 0.72 [0.16, 1.21] <0.0001a 
3 51 0.45 ± 0.60 0.28 [0.04, 0.88] <0.001c 
4 or 5 54 0.52 ± 0.59 0.37 [0.09, 0.84] <0.0001c 
6 months 
0 11 0.09 ± 0.55 0.07 [-0.15, 0.16] 0.63a 
0.27 
1 11 0.13 ± 0.46 0.04 [-0.16, 0.30] 0.40a 
2 25 -0.13 ± 0.40 -0.14 [-0.32, 0.01] 0.14a 
3 46 -0.06 ± 0.38 -0.08 [-0.22, 0.14] 0.10c 
4 or 5 46 -0.12 ± 0.42 -0.09 [-0.32, 0.09] 0.07a 
12 months 
0 14 -0.07 ± 0.11 -0.08 [-0.16, 0] 0.08a 
0.94 
1 12 -0.05 ± 0.10 -0.05 [-0.11, -0.01] 0.14a 
2 26 -0.11 ± 0.13 -0.07 [-0.18, -0.01] <0.001c 
3 41 -0.09 ± 0.12 -0.06 [-0.17, -0.03] <0.0001a 
4 or 5 48 -0.10 ± 0.20 -0.05 [-0.18, -0.01] <0.001c 
18 months 
0 12 -0.02 ± 0.14 -0.06 [-0.10, 0.08] 0.73a 
0.94 
1 9 -0.03 ± 0.20 -0.03 [-0.09, 0.06] 0.72a 
2 21 -0.03 ± 0.11 -0.04 [-0.06, 0] 0.03b 
3 44 -0.03 ± 0.05 -0.03 [-0.06, 0] 0.001a 
4 or 5 47 -0.03 ± 0.12 -0.02 [-0.08, 0] 0.02b 
24 months 
0 11 -0.05 ± 0.07 0 [-0.12, 0] 0.22b 
0.18 
1 13 -0.03 ± 0.14 -0.05 [-0.07, -0.03] 0.07c 
2 22 -0.10 ± 0.13 -0.06 [-0.11, 0] <0.001c 
3 43 -0.04 ± 0.07 -0.01 [-0.05, 0] <0.01c 
4 or 5 46 -0.05 ± 0.09 -0.02 [-0.06, 0] <0.0001c 
*Values are calculated by the change in subject / the difference of exact days since diagnosis between two follow-
ups in months, in ng/mL/month. Between P values are obtained from Kruskal-Wallis test. Within P values are 
obtained from paired sample test. a Based on t-test. b Based on Wilcoxon signed rank test. c Based on sign test. 
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Figure 18. Trajectory plot for mean and median rate (exact) of change of C-peptide for different number of 
positive autoantibodies at baseline 
 
Left three are the trajectory of mean value of the rate of change of C-peptide from onset, 3 months, and previous 
visit, respectively. Right three are the trajectory of median value of the rate of change of C-peptide from onset, 3 
months, and previous visit. Values are calculated by the change in subject / the difference of exact days since 
diagnosis between two follow-ups in months, in ng/mL/month. 
 
61 
A.6 LINEAR MIXED MODELS (ACTUAL SCALE OF C-PEPTIDE) 
Table 26. Variables considered in univariate random coefficients models for C-peptide and change of C-
peptide from onset at 3 months and forward 
 
Variables 
C-peptide Change of C-peptide from onset 
Coefficient P value Coefficient P value 
Age at diagnosis (years) 0.1345 <0.0001 0.1054 <0.0001 
Puberty (prepuberty is reference) 0.8332 <0.0001 0.6557 <0.0001 
Age at diagnosis (categorical) 
       0-4 
       5-9 
       10-14 
       ≥ 15 
 
(ref) 
0.3773 
1.1171 
1.4810 
<0.0001 
 
(ref) 
0.3095 
0.8735 
1.1807 
<0.0001 
     
Gender (male is reference) 0.2939 0.0798 0.08335 0.5444 
IDAA1c at 3-month visit -0.1952 0.0009 -0.1387 0.0034 
     
Days since diagnosis -0.00198 <0.0001 -0.00197 <0.0001 
Visits (3, 6, 12, 18, and 24 months) -0.06237 <0.0001 -0.06187 <0.0001 
Visits (categorical) 
       3 months 
       6 months 
       12 months 
       18 months 
       24 months 
 
(ref) 
-0.1768 
-0.7518 
-1.3216 
-0.9436 
<0.0001 
 
(ref) 
-0.1786 
-0.7543 
-0.9390 
-1.3176 
<0.0001 
     
Overweight status at onset  
(Non-overweight is reference) 0.5553 0.0057 0.2321 0.1612 
Overweight status at 3 months 
(Non-overweight is reference) 0.2516 0.1639 0.1953 0.1864 
Overweight status at onset and 3-month visit 
      Overweight – Overweight 
      Overweight – Non-overweight 
      Non-overweight – Overweight 
      Non-overweight – Non-overweight 
 
 
0.4992 
1.1123 
-0.01722 
(ref) 
0.0343 
 
 
0.2261 
0.5252 
0.1183 
(ref) 
0.4537 
     
# positive baseline Abs 
       0 
       1 
       2 
       3 
       4 or 5 
 
(ref) 
-0.2572  
-0.3343 
-0.5188 
-0.5606 
0.3783 
 
(ref) 
-0.09219 
-0.1333 
-0.3887 
-0.4095 
0.2958 
2 or more positive Abs at baseline -0.3833 0.0836 -0.3049 0.0921 
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Table 27. Multivariate analysis for C-peptide and change of C-peptide from onset over 3 months and forward 
(Model A and C) 
 
Covariates C-peptide at 3 months and forward 
Change of C-peptide from onset of 3 
months and forward 
Fixed effects (SE) P value Fixed effects (SE) P value 
Model A: Times are days since diagnosis 
IDAA1c at 3 months -0.1554 (0.04687) 0.0012 -0.1141 (0.04247) 0.0082 
Female 0.4419 (0.1491) 0.0036 0.2231 (0.1351) 0.1010 
Age at diagnosis 0.1436 (0.02059) <0.0001 0.1071 (0.01865) <0.0001 
2 or more Abs+ at baseline -0.3948 (0.1986) 0.0489 -0.2694 (0.1802) 0.1372 
Days since diagnosis -0.00184 (0.000198) <0.0001 -0.00183 (0.000198) <0.0001 
Overweight at onset 0.7655 (0.2720) 0.0056 0.4354 (0.2427) 0.0751 
Overwt_onset * dsddx -0.00059 (0.000428) 0.1711 -0.00055 (0.000428) 0.2036 
Model C: Times are follow-ups in months coded as 3, 6, 12, 18, and 24 in months as categorical 
IDAA1c at 3 months -0.1992 (0.04835) <0.0001 -0.1399 (0.04257) 0.0013 
Female 0.4584 (0.1536) 0.0034 0.2317 (0.1354) 0.0894 
Age at diagnosis 0.1488 (0.02109) <0.0001 0.1106 (0.01862) <0.0001 
2 or more Abs+ at baseline -0.3131 (0.2048) 0.1286 -0.2282 (0.1806) 0.2085 
6 months -0.1079 (0.1192) 
<0.0001 
-0.1118 (0.1189) 
<0.0001 12 months -0.6630 (0.1167) -0.6673 (0.1165) 18 months -0.9003 (0.1195) -0.8975 (0.1192) 
24 months -1.1975 (0.1206) -1.1941 (0.1202) 
Overweight at onset 0.8214 (0.2353) 0.0056 0.5052 (0.2190) 0.1943 
Overweight at onset * 6 months -0.3225 (0.2544) 
0.2058 
-0.3006 (0.2538) 
0.2387 Overweight at onset * 12 months -0.4936 (0.2559) -0.4891 (0.2553) Overweight at onset * 18 months -0.1926 (0.2628) -0.1845 (0.2621) 
Overweight at onset * 24 months -0.5381 (0.2577) -0.5065 (0.2570) 
 
Table 28. Comparison of estimated means of C-peptide and change of C-peptide from onset between 
overweight and non-overweight subjects at each follow-up (Model C) 
 
Visits C-peptide  Change of C-peptide from onset  Mean difference (95% C.I.) P value Mean difference (95% C.I.) P value 
3 months 0.8214 (0.3586, 1.2843) 0.0005 0.5052 (0.07460, 0.9358) 0.0216 
6 months 0.4989 (0.01230, 0.9854) 0.0445 0.2046 (-0.2510, 0.6602) 0.3780 
12 months 0.3278 (-0.1621, 0.8178) 0.1891 0.01609 (-0.4430, 0.4752) 0.9451 
18 months 0.6288 (0.1256, 1.1320) 0.0145 0.3207 (-0.1524, 0.7937) 0.1835 
24 months 0.2833 (-0.2098, 0.7763) 0.2593 -0.00130 (-0.4637, 0.4611) 0.9956 
Overall across time 0.5120 (0.1526, 0.8715) 0.0056 0.2090 (-0.1079, 0.5260) 0.1943 
* For model C: Times are follow-ups in months coded as 3, 6, 12, 18, and 24 in months as categorical Values are in 
ng/mL. P values were obtained from t-test for testing the estimates are different from 0 or not. 
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Figure 19. Spaghetti plots for observed and fitted values of C-peptide in Model A 
Left three are observed values for C-peptide. Right three are fitted values for C-peptide. Model A: time was treated 
as days since diagnosis. 
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Figure 20. Spaghetti plots for observed and fitted values of C-peptide in Model C 
Left three are observed values for C-peptide. Right three are fitted values for C-peptide. Model C: time was treated 
as follow-ups in months as categorical, coded as 3, 6, 12, 18, and 24. 
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Figure 21. Spaghetti plots for observed and fitted values of change of C-peptide from onset in Model A 
Left three are observed values for change of C-peptide from onset. Right three are fitted values for change of C-
peptide from onset. Model A: time was treated as days since diagnosis. 
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Figure 22. Spaghetti plots for observed and fitted values of change of C-peptide from onset in Model C 
Left three are observed values for change of C-peptide from onset. Right three are fitted values for change of C-
peptide from onset. Model C: time was treated as follow-ups in months as categorical, coded as 3, 6, 12, 18, and 24. 
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Figure 23. Pearson residuals plots of models A, B, and C for C-peptide and change of C-peptide from onset at 
3 months and subsequent follow-ups 
A, B, and C were Pearson residuals plots of random coefficients models A, B, and C separately for C-peptide at 3 
months and forward follow-ups. D, E, and F were Pearson residuals plots of random coefficients models A, B, and C 
separately for change of C-peptide from onset at 3 months and forward follow-ups. 
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A.7 LINEAR MIXED MODEL (LOG-TRANSFORMED C-PEPTIDE) 
Table 29. Multivariate analysis for log-transformed C-peptide and log-ratio of C-peptide to onset of each 
follow-up 
 
Covariates 
Log-transformed C-peptide at 3 
months and forward 
Log-ratio of C-peptide of each 
follow-up to onset 
Fixed effects (SE) P value Fixed effects (SE) P value 
Model A: Times are days since diagnosis 
IDAA1c at 3 months -0.2207 (0.03587) <0.0001 -0.1553 (0.03683) <0.0001 
Female 0.2849 (0.1141) 0.0137 0.1092 (0.1171) 0.3527 
Age at diagnosis 0.1184 (0.01567) <0.0001 0.07974 (0.01608) <0.0001 
2 or more Abs+ at baseline -0.1850 (0.1522) 0.2265 -0.1623 (0.1562) 0.3007 
Days since diagnosis -0.00249 (0.000192) <0.0001 -0.00249 (0.000191) <0.0001 
Overweight at onset 0.08269 (0.1692) 0.6258 -0.2476 (0.1740) 0.1571 
Overwt_onset * dsddx 0.000426 (0.000419) 0.3110 0.000432 (0.000417) 0.3024 
Model B: Times are follow-ups in months coded as 3, 6, 12, 18, and 24 as continuous 
IDAA1c at 3 months -0.2172 (0.03614) <0.0001 -0.1518 (0.03692) <0.0001 
Female 0.2761 (0.1149) 0.0176 0.10000 (0.1174) 0.3957 
Age at diagnosis 0.1185 (0.01580) <0.0001 0.07999 (0.01613) <0.0001 
2 or more Abs+ at baseline -0.1968 (0.1535) 0.2019 -0.1735 (0.1567) 0.2702 
Follow-up visits (in months) -0.07859 (0.005983) <0.0001 -0.07847 (0.005953) <0.0001 
Overweight at onset 0.04695 (0.1755) 0.7895 -0.2842 (0.1799) 0.1167 
Overweight at onset * visits 0.01536 (0.01302) 0.2402 0.01562 (0.01295) 0.2302 
Model C: Times are follow-ups in months coded as 3, 6, 12, 18, and 24 as categorical 
IDAA1c at 3 months -0.2192 (0.03651) <0.0001 -0.1535 (0.03707) <0.0001 
Female 0.3115 (0.1161) 0.0082 0.1322 (0.1179) 0.2642 
Age at diagnosis 0.1352 (0.01597) <0.0001 0.09545 (0.01620) <0.0001 
2 or more Abs+ at baseline -0.2861 (0.1549) 0.0669 -0.2580 (0.1572) 0.1030 
6 months -0.1456 (0.1015) 
<0.0001 
-0.1465 (0.1014) 
<0.0001 12 months -0.7129 (0.09944) -0.7138 (0.09932) 18 months -1.1933 (0.1018) -1.1912 (0.1017) 
24 months -1.6300 (0.1027) -1.6251 (0.1025) 
Overweight at onset 0.05248 (0.1874) 0.0547 -0.2820 (0.1888) 0.6724 
Overweight at onset * 6 months 0.1512 (0.2167) 
0.2033 
0.1685 (0.2164) 
0.1902 Overweight at onset * 12 months 0.1067 (0.2180) 0.1105 (0.2177) Overweight at onset * 18 months 0.5046 (0.2238) 0.5082 (0.2235) 
Overweight at onset * 24 months 0.3069 (0.2194) 0.3272 (0.2192) 
* In model C, 3 months was the reference. 
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Table 30. Estimated mean ratio of C-peptide and the ratio of C-peptide ratio to onset for each follow-up 
between overweight and non-overweight subjects 
 
Visits Ratio of C-peptide  Ratio of C-peptide ratio to onset  Mean difference (95% C.I.) P value Mean difference (95% C.I.) P value 
Model B: Times are follow-ups in months coded as 3, 6, 12, 18, and 24 as continuous 
3 months 1.0975 (0.8103, 1.4866) 0.5452 0.7887 (0.5773, 1.0774) 0.1346 
6 months 1.1492 (0.8732, 1.5127) 0.3183 0.8265 (0.6233, 1.0960) 0.1840 
12 months 1.2602 (0.9528, 1.6670) 0.1042 0.9077 (0.6842, 1.2042) 0.4990 
18 months 1.3820 (0.9652, 1.9788) 0.0769 0.9968 (0.6974, 1.4249) 0.9860 
24 months 1.5154 (0.9407, 2.4415) 0.0869 1.0947 (0.6829, 1.7549) 0.7047 
Overall across time 1.0481 (0.7406, 1.4833) 0.7895 0.7526 (0.5271, 1.0745) 0.1167 
Model C: Times are follow-ups in months coded as 3, 6, 12, 18, and 24 as categorical 
3 months 1.0539 (0.7291, 1.5235) 0.7796 0.7543 (0.5203, 1.0934) 0.1362 
6 months 1.2258 (0.8301, 1.8103) 0.3051 0.8928 (0.6030, 1.3218) 0.5702 
12 months 1.1725 (0.7916, 1.7367) 0.4263 0.8424 (0.5673, 1.2509) 0.3944 
18 months 1.7456 (1.1646, 2.6164) 0.0071 1.2538 (0.8344, 1.8840) 0.2756 
24 months 1.4325 (0.9644, 2.1274) 0.0749 1.0462 (0.7026, 1.5578) 0.8235 
Overall across time 1.3051 (0.9945, 1.7129) 0.0547 0.9426 (0.7153, 1.2421) 0.6724 
* P values were obtained from t-test for testing the estimates are different from 0 or not. 
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Figure 24. Spaghetti plots for observed and fitted values of log-transformed C-peptide in Model A 
Left three are observed values for log-transformed C-peptide at 3 months and forward. Right three are fitted values 
for log-transformed C-peptide at 3 months and forward. Model A: time was treated as days since diagnosis. 
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Figure 25. Spaghetti plots for observed and fitted values of log-transformed C-peptide in Model B 
Left three are observed values for log-transformed C-peptide at 3 months and forward. Right three are fitted values 
for log-transformed C-peptide at 3 months and forward. Model B: time was treated as continuous in 3, 6, 12, 18, and 
24 months. 
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Figure 26. Spaghetti plots for observed and fitted values of log-transformed C-peptide in Model C 
Left three are observed values for log-transformed C-peptide at 3 months and forward. Right three are fitted values 
for log-transformed C-peptide at 3 months and forward. Model C: time was treated as categorical in 3, 6, 12, 18, and 
24 months. 
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Figure 27. Spaghetti plots for observed and fitted values of log-ratio of C-peptide to onset in Model A 
Left three are observed values for log-ratio of C-peptide to onset at 3 months and forward. Right three are fitted 
values for log-ratio of C-peptide to onset at 3 months and forward. Model A: time was treated as days since 
diagnosis. 
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Figure 28. Spaghetti plots for observed and fitted values of log-ratio of C-peptide to onset in Model B 
Left three are observed values for log-ratio of C-peptide to onset at 3 months and forward. Right three are fitted 
values for log-ratio of C-peptide to onset at 3 months and forward. Model B: time was treated as continuous in 3, 6, 
18, and 24 months. 
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Figure 29. Spaghetti plots for observed and fitted values of log-ratio of C-peptide to onset in Model C 
Left three are observed values for log-ratio of C-peptide to onset at 3 months and forward. Right three are fitted 
values for log-ratio of C-peptide to onset at 3 months and forward. Model C: time was treated as categorical in 3, 6, 
18, and 24 months. 
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Figure 30. Pearson residuals plots of models A, B, and C for log-transformed C-peptide and log-ratio of C-
peptide to onset at 3 months and subsequent follow-ups 
 
A, B, and C were Pearson residuals plots of random coefficients models A, B, and C separately for log-transformed 
C-peptide at 3 months and forward follow-ups. D, E, and F were Pearson residuals plots of random coefficients 
models A, B, and C separately for log-ratio of C-peptide to onset at 3 months and forward follow-ups. 
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APPENDIX B: SAS CODE FOR TESTING AND MODELING 
1. Paired-sample test (t-test, signed rank test, and sign test; normality test)
*--- Paired-sample t-test and nonparametric tests in each visit ; 
%macro onesample_test(testvar, levelvar, timevar, title); 
proc sort data=thesis.Analysis_cpeptide; 
by &levelvar; 
run; 
proc univariate data=thesis.Analysis_cpeptide normal; 
var &testvar; 
by &levelvar ; 
class &timevar; 
where &levelvar ne .; 
*histogram/normal kernel(l=2);
qqplot/normal(l=1 mu=est sigma=est) square;
title &title;
run; 
%mend; 
title; 
2. Two-sample test (t-test, and nonparametric test)
*--- Summary statistics ; 
%macro sumry_grp(testvar, levelvar, timevar, title); 
proc sort data=thesis.Analysis_cpeptide; 
by &levelvar; 
run; 
proc means nolabels data=thesis.Analysis_cpeptide n nmiss mean std 
median p25 p75 min max maxdec=2; 
var &testvar ; 
class &timevar ; 
by &levelvar; 
title &title ; 
run; 
title; 
%mend; 
*--- Two-sample t-test ; 
%macro ttest_2sample(testvar, levelvar, timevar, title); 
proc sort data=thesis.Analysis_cpeptide; 
by &timevar; 
run; 
proc ttest data=thesis.Analysis_cpeptide ; 
class &levelvar ; 
var &testvar ; 
by &timevar ; 
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title &title ; 
run; 
%mend ; 
*--- Wilcoxon-Mann-Whitney test: nonparametric two-sample t-test ; 
%macro npar_2sample(testvar, levelvar, timevar, title); 
proc sort data=thesis.Analysis_cpeptide; 
by &timevar; 
run; 
proc npar1way data=thesis.Analysis_cpeptide wilcoxon; 
class &levelvar ; 
var &testvar ; 
by &timevar ; 
title &title ; 
run; 
%mend ; 
title; 
3. Multiple-sample test (Nonparametric ANOVA test, and DSCF comparisons)
*--- Summary statistics ; 
%macro sumry_grp(testvar, levelvar, timevar, title); 
proc sort data=thesis.Analysis_cpeptide; 
by &levelvar; 
run; 
proc means nolabels data=thesis.Analysis_cpeptide n nmiss mean std 
median p25 p75 min max maxdec=2; 
var &testvar ; 
class &timevar ; 
by &levelvar; 
title &title ; 
run; 
title; 
%mend; 
*--- Kruskal Wallis test (nonparametric ANOVA test) and multiple comparisons 
; 
%macro npar_ANOVA(testvar, levelvar, timevar, title); 
proc sort data=thesis.Analysis_cpeptide; 
by &timevar; 
run; 
proc npar1way data=thesis.Analysis_cpeptide Wilcoxon dscf; 
class &levelvar ; 
var &testvar ; 
by &timevar ; 
title &title ; 
run; 
%mend ; 
4. Trajectory plot for mean and median by group
*--- Print out the descriptive stats ; 
%macro traj_grp_cpep(testvar, levelvar, group, stats); 
proc means data=thesis.Analysis_cpeptide maxdec=2 noprint; 
var &testvar; 
class plotwindow; 
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  where &levelvar=&group; 
  output out=cpep_&group &stats=&stats; 
 run; 
 data cpep_&group; 
  set cpep_&group; 
  if plotwindow ne .; 
  &levelvar=&group; 
 run; 
 proc sort; 
  by plotwindow &levelvar ; 
 run; 
%mend; 
 
*--- Merge all the dataset for each group ; 
%macro merge_grp_cpep(datasets, levelvar); 
 data cpep_grp; 
  set &datasets; 
  by plotwindow &levelvar; 
 run; 
%mend; 
 
*--- Trajectory for median ; 
%macro p50plot_grp_cpep(levelvar, frm, lower, upper, step, ylabel, title); 
 goptions reset=all; 
 SYMBOL1 V=star C=black I=join h=4; 
 SYMBOL2 V=triangle C=black I=join h=4; 
SYMBOL3 V=circle C=black I=join h=4; 
 SYMBOL4 V=plus C=black I=join h=4; 
 SYMBOL5 V=- C=black I=join h=4; 
 legend label=none down=3 position=(top right inside) mode=share 
cborder=black; 
 axis1 label=(angle=90 &ylabel) order=(&lower to &upper by &step); 
 axis2 offset=(6, 6) label=('Onset and follow-up visits') order=(0 to 24 
by 3) split=' '; 
 proc gplot data=cpep_grp; 
  plot median*plotwindow=&levelvar/haxis=axis2 vaxis=axis1 noframe 
legend=legend; 
  format &levelvar &frm ; 
  title &title; 
 run; 
 quit; 
 title; 
%mend; 
 
*--- Trajectory for mean ; 
%macro meanplot_grp_cpep(levelvar, frm, lower, upper, step, ylabel, title); 
 goptions reset=all; 
 SYMBOL1 V=dot C=black I=join h=2; 
 SYMBOL2 V=square C=black I=join h=4; 
      SYMBOL3 V=diamond C=black I=join h=4; 
 SYMBOL4 V=x C=black I=join h=4; 
 SYMBOL5 V=+ C=black I=join h=4; 
 legend label=none down=3 position=(top right inside) mode=share 
cborder=black; 
 axis1 label=(angle=90 &ylabel) order=(&lower to &upper by &step); 
 axis2 offset=(6, 6) label=('Onset and follow-up visits') order=(0 to 24 
by 3) split=' '; 
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 proc gplot data=cpep_grp; 
  plot mean*plotwindow=&levelvar/haxis=axis2 vaxis=axis1 noframe 
legend=legend; 
  format &levelvar &frm ; 
  title &title; 
 run; 
 quit; 
 title; 
%mend; 
 
5. Box plots with mean and median 
*--- Box plots by group ; 
 
proc sort data=thesis.Analysis_cpeptide; 
 by plotwindow; 
run; 
 
%macro box_grp(var, levelvar, group, ylabel, lower, upper, scale, title); 
 *--- Use the UNIVARIATE procedure to determine the mean and median 
values ; 
  proc univariate data=thesis.Analysis_cpeptide noprint;  
   var &var;  
   where &levelvar=&group ;  
   by plotwindow;  
   output mean=mean median=median out=stat;  
  run; 
 *--- Merge the mean and median values back into the original data set 
by drawwindow ; 
  data all;  
   merge thesis.Analysis_cpeptide stat;  
   by plotwindow;   
   if &levelvar=&group;  
   keep plotwindow &var mean median; 
  run;                 
 *--- Reshape the data set to create a category variable to use to 
generate the legend ; 
  data reshape;  
   set all;  
   length zvar $8;  
   newy=&var; zvar='Box'; output;  
   newy=mean; zvar='Mean'; output;  
   newy=median; zvar='Median'; output;  
  run;  
 *--- Create the graph ; 
  goptions reset=all interpol=boxt; 
  symbol1 width=1.85 bwidth=7 value=circle c=black; 
  symbol2 interpol=none color=black height=1.8 value=plus;  
  symbol3 interpol=none color=black height=1.8 value=diamond;  
  axis1 label=(angle=90 &ylabel) order=(&lower to &upper by 
&scale); 
  axis2 offset=(6,6) label=('Onset and follow-up visits') order=(0 
to 24 by 3) split=' '; 
  legend order=('Mean' 'Median') repeat=1 label=none;  
  proc gplot data = reshape; 
   title &title; 
   plot newy*plotwindow=zvar /vaxis=axis1 haxis=axis2 noframe 
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legend=legend; 
  run; 
  quit; 
  title; 
%mend; 
 
6. Spaghetti plots 
*--- Spaghetti plot for overall ; 
%macro spaghetti_overall(dependent_var, indep_var, xvalues, xlabel, yvalues, 
ylabel, title); 
 options nobyline; 
 title &title; 
 proc sgplot data = thesis.Analysis_cpeptide;  
  where drawwindow ne 0; 
  series x = &indep_var y = &dependent_var / group = pid ; 
  pbspline y=&dependent_var x=&indep_var / nomarkers lineattrs = 
(color= black pattern = 1 thickness = 5) legendlabel='Overall Spline' 
name='spline1'; 
  xaxis values = &xvalues label=&xlabel; 
  yaxis values = &yvalues label=&ylabel; 
  keylegend 'spline1'; 
 run; 
 title; 
 quit; 
%mend; 
 
*--- Spaghetti plot by group ; 
%macro spaghetti_grp(dependent_var, indep_var, group_var, grp_value, xvalues, 
xlabel, yvalues, ylabel, title); 
 options nobyline; 
 title &title; 
 proc sgplot data = thesis.Analysis_cpeptide;  
  by &group_var; 
  where drawwindow ne 0 and &group_var=&grp_value; 
  series x = &indep_var y = &dependent_var / group = pid ; 
  pbspline y=&dependent_var x=&indep_var / nomarkers lineattrs = 
(color= black pattern = 1 thickness = 5) legendlabel='Overall Spline' 
name='spline1'; 
  xaxis values = &xvalues label=&xlabel; 
  yaxis values = &yvalues label=&ylabel; 
  keylegend 'spline1'; 
 run; 
 title; 
 quit; 
%mend; 
 
 
7. Random coefficient model 
*--- Fit model, save the fitted values into out_dataset, and check residuals; 
%macro model_randcoef(class_var, dependent_var, fixed_var, random_var, 
covtype, title1, title2); 
 title1 &title1; 
 title2 &title2; 
 proc mixed data=thesis.complete_visit_cpeptide order=data covtest ; 
  *--- Define categorical variables ; 
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  class &class_var ; 
  *--- Fit the mean structure ; 
  model &dependent_var = &fixed_var /solution ddfm=kr 
 outp=&out_dataset residual; 
  where drawwindow ne 0 ; 
  *--- Fit random effects ; 
  random &random_var / subject=pid type=&covtype g v vcorr; 
 run; 
 title; 
%mend; 
 
8. Spaghetti plot for fitted values 
*--- Spaghetti plot for overall fitted value ; 
%macro spaghetti_overall_fitted(dataset, dependent_var, indep_var, xvalues, 
xlabel, ylabel, title); 
 proc sort data=&dataset ; 
  by &indep_var ; 
 run; 
 
 options nobyline; 
 title &title; 
 proc sgplot data = &dataset;  
  where drawwindow ne 0; 
  series x = &indep_var y = &dependent_var / group = pid ; 
  xaxis values = &xvalues label=&xlabel; 
  yaxis label=&ylabel; 
 run; 
 title; 
 quit; 
%mend; 
*--- Spaghetti plot for fitted value by group ; 
%macro spaghetti_grp_fitted(dataset, group_var, grp_value, dependent_var, 
indep_var, xvalues, xlabel, ylabel, title); 
 proc sort data=&dataset ; 
  by &indep_var ; 
 run; 
 
 options nobyline; 
 title &title; 
 proc sgplot data = &dataset;  
  where drawwindow ne 0 and &group_var=&grp_value ; 
  series x = &indep_var y = &dependent_var / group = pid ; 
  xaxis values = &xvalues label=&xlabel; 
  yaxis label=&ylabel; 
 run; 
 title; 
 quit; 
%mend; 
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